lamotrigine has been researched along with Pregnancy in 220 studies
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lamotrigine is the most widely used anti-epileptic drug in pregnancy because of its low teratogenicity." | 9.22 | Dosage Optimization of Lamotrigine in Pregnancy: A Pharmacometric Approach Using Modeling and Simulation. ( G, SS; Kp, A; Pa, B; Thomas, G, 2022) |
| "To prospectively analyse the pharmacokinetics of lamotrigine (LTG) during pregnancy and lactation in a consecutive series of epileptic pregnant women." | 9.14 | Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. ( Bauer, S; Dudenhausen, JW; Fotopoulou, C; Henrich, W; Kretz, R; Schefold, JC; Schmitz, B, 2009) |
| " This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin, carbamazepine, phenobarbital, and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy." | 9.12 | Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications. ( Demir, O; Kaplan, YC, 2021) |
| "In eight women treated with lamotrigine monotherapy, the lamotrigine dose/plasma concentration (D/C) ratio increased by 295% from baseline outside pregnancy to midgestation, whereas in six women treated with lamotrigine in combination with valproate, the increase was only 60%." | 9.12 | Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. ( Luef, G; Ohman, I; Pittschieler, S; Sabers, A; Tomson, T, 2006) |
| "This paper reviewed the relevant literature on the effects of lamotrigine on pregnancy outcomes to provide useful information regarding lamotrigine use in pregnant women with bipolar disorder." | 8.98 | The risks associated with the use of lamotrigine during pregnancy. ( Gao, Z; Kong, L; Wang, B; Wang, C; Zhou, T, 2018) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 8.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "The International Lamotrigine Pregnancy Registry monitored for a signal of a substantial increase in the frequency of major congenital malformations associated with lamotrigine exposures in pregnancy over an 18-year period." | 8.90 | Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry. ( Cragan, J; Cunnington, M; Lowensohn, R; Messenheimer, J; Sinclair, S; Tennis, P; Weil, J; Yerby, M, 2014) |
| "The paper presents the review of literature on the age aspect of using lamotrigine in pubertal period, in women of reproductive age, during pregnancy and lactation and in climacteric period." | 8.87 | [Lamotrigine in treatment of women with epilepsy]. ( Agranovich, OV; Dranko, DV; Vlasov, PN, 2011) |
| " We present three cases of women exposed to lamotrigine during pregnancy and breastfeeding, with follow up of their infants until 15-18 months of development." | 8.85 | Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. ( Epperson, CN; Gonzalez, J; Kim, DR; O'Reardon, JP; Wakil, L, 2009) |
| "To provide an overview of the available literature concerning the prevention of congenital malformations following the use of lamotrigine (LMT) during pregnancy." | 8.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| "Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy." | 8.31 | Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. ( Barry, JM; Birnbaum, AK; French, JA; Harden, CL; Karanam, A; Pennell, PB, 2023) |
| "During pregnancy, various physiological changes occur that can alter the pharmacokinetics of antiepileptic drugs, such as lamotrigine (LTG)." | 8.02 | Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. ( Cao, YF; Guo, Y; Sun, XY; Tao, YY; Wang, ML; Wang, ZY; Zhao, L, 2021) |
| "This study was carried out to determine changes over time in use of folic acid, anti-epileptic drugs (AED), seizures during pregnancy and malformation rate over two decades in women with epilepsy enrolled in the Kerala registry of Epilepsy and Pregnancy (KREP)." | 7.96 | Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. ( A S, R; Baishya, J; Jose, M; Keni, RR; Sankara Sarma, P; Thomas, SV, 2020) |
| "To evaluate the pharmacokinetic changes in lamotrigine (LTG) from prepregnancy to postpartum and to assess the impact of therapeutic drug monitoring (TDM) on seizure management during pregnancy in a Chinese population." | 7.91 | Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. ( Ding, Y; Guo, Y; Tan, X; Zhang, S, 2019) |
| "To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications." | 7.88 | Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Pennell, PB, 2018) |
| "To evaluate the impact of maternal UGT1A4 and UGT2B7 genetic polymorphisms and sex of foetus on gestation-induced changes in lamotrigine (LTG) clearance during pregnancy and post-partum (PP)." | 7.88 | UGT polymorphisms and lamotrigine clearance during pregnancy. ( Ekström, L; Hansen, TF; Öhman, I; Petrenaite, V; Sabers, A; Sæbye, D; Tomson, T, 2018) |
| " Among all mood stabilizers, lithium has the largest evidence base for efficacy in the peripartum period, but lamotrigine is increasingly prescribed for bipolar spectrum disorders during pregnancy." | 7.85 | Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: A population-based cohort study. ( Bergink, V; Clark, CT; Kushner, SA; Liu, X; Munk-Olsen, T; Wesseloo, R, 2017) |
| "Callers who contacted the Israeli Teratology Information Service regarding lamotrigine treatment or NTE during pregnancy between 1997 and 2008 were prospectively followed-up." | 7.85 | Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. ( Diav-Citrin, O; Finkel-Pekarsky, V; Ornoy, A; Shechtman, S; Zvi, N, 2017) |
| "Here, we present the outcomes in the subset of six women who were treated with lamotrigine 100-400 mg/day for the entire pregnancy." | 7.83 | Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand. ( Hatters-Friedman, S; Moller-Olsen, C; North, A; Prakash, C, 2016) |
| "Little information is available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder." | 7.79 | Lamotrigine dosing for pregnant patients with bipolar disorder. ( Clark, CT; Helsel, J; Klein, AM; Perel, JM; Wisner, KL, 2013) |
| "Treatment with lamotrigine (LTG) during pregnancy is associated with a pronounced risk of seizure deterioration, because pregnancy accelerates LTG elimination." | 7.78 | Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. ( Sabers, A, 2012) |
| "To investigate the physiological mechanisms behind the pronounced decline of lamotrigine (LTG) serum concentrations during pregnancy." | 7.77 | Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. ( Bråthen, G; Brodtkorb, E; Helde, G; Reimers, A, 2011) |
| "Health care providers reported lamotrigine exposure during pregnancy, and subsequent outcomes, on a voluntary basis." | 7.77 | Final results from 18 years of the International Lamotrigine Pregnancy Registry. ( Cunnington, MC; Ferber, S; Messenheimer, JA; Tennis, P; Weil, JG; Yerby, M, 2011) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 7.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 7.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "Oral clearance of lamotrigine, an antiepileptic drug commonly used in pregnant women, is increased in pregnancy by unknown mechanisms." | 7.75 | Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. ( Chen, H; Choi, S; Fischer, JH; Jeong, H; Yang, K, 2009) |
| "Lamotrigine is frequently used to manage epilepsy during pregnancy." | 7.75 | Lamotrigine and twin pregnancy, incidental event or possible correlation? ( Azimi, AR; Karvigh, SA; Motamedi, M; Navardi, S; Sahraian, MA, 2009) |
| "To report a case of severe apnea in an infant exposed to lamotrigine through breast-feeding." | 7.75 | Severe apnea in an infant exposed to lamotrigine in breast milk. ( Aronsen, L; Nordmo, E; Småbrekke, L; Vorren, S; Wasland, K, 2009) |
| "We prospectively surveyed 23 pregnant women with epilepsy on lamotrigine monotherapy and reported outcome of their pregnancies, including one fetal intrauterine death, one spontaneous abortion and two preterm deliveries." | 7.75 | Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy--aspects of pre-pregnancy counseling and drug monitoring. ( Bakulić, TI; Bosnjak-Pasić, M; Cvitanović-Sojat, L; Demarin, V; Fucić, A; Gjergja-Juraski, R; Mikula, I; Miskov, S, 2009) |
| "To assess changes in the pharmacokinetics of the anti-epileptic drug lamotrigine (LTG) during pregnancy, plasma LTG concentrations at steady-state were determined at different intervals during 11 pregnancies in 10 women with epilepsy stabilized on long-term LTG therapy." | 7.74 | Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. ( Franco, V; Gatti, G; La Neve, A; Mazzucchelli, I; Ozkaynakçi, AE; Papantonio, A; Perucca, E; Specchio, LM, 2008) |
| "We describe the case of a pregnancy healthy outcome after in utero consecutive exposure to lamotrigine and citalopram." | 7.74 | Consecutive exposure to lamotrigine and citalopram during pregnancy. ( Gentile, S; Vozzi, F, 2007) |
| "To characterize the magnitude and course of alterations in total and free lamotrigine (LTG) clearance (Cl) during pregnancy and the postpartum period, to assess the impact of therapeutic drug monitoring (TDM) on seizure frequency, to determine the ratio to individual target LTG concentration that is associated with increased seizure risk, and to evaluate maternal postpartum toxicity." | 7.74 | Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. ( Holley, DK; Koganti, A; Newman, M; Newport, DJ; Peng, L; Pennell, PB; Ritchie, JC; Stowe, ZN, 2008) |
| "To further characterize pregnancy-induced alterations in the pharmacokinetics of lamotrigine (LTG)." | 7.74 | Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. ( Beck, O; Ohman, I; Tomson, T; Vitols, S, 2008) |
| "The infant exposed in the first trimester of pregnancy to the anticonvulsant drug lamotrigine has an increased risk to have an isolated cleft palate or cleft lip deformity." | 7.74 | Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. ( Baldwin, EJ; Glassman, L; Habecker, E; Holmes, LB; Smith, CR; Wong, SL; Wyszynski, DF, 2008) |
| "To report the frequency of major malformations in lamotrigine-exposed pregnancies from September 1, 1992, through March 31, 2004, in the International Lamotrigine Pregnancy Registry." | 7.73 | Lamotrigine and the risk of malformations in pregnancy. ( Cunnington, M; Tennis, P, 2005) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 7.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| "This study was performed to clarify alterations in lamotrigine (LTG) clearance during pregnancy and childbirth." | 7.72 | The impact of pregnancy and childbirth on the metabolism of lamotrigine. ( Helmers, SL; Henry, TR; Montgomery, JQ; Newport, DJ; Pennell, PB; Stowe, ZN, 2004) |
| "To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy." | 7.71 | Lamotrigine clearance during pregnancy. ( Blesi, K; Leppik, IE; Remmel, R; Sathanandan, ST; Tran, TA, 2002) |
| "In 1992, the International Lamotrigine Pregnancy Registry was initiated to enroll prospectively and to monitor pregnancies exposed to lamotrigine (LTG) for the occurrence of major birth defects." | 7.71 | Preliminary results on pregnancy outcomes in women using lamotrigine. ( Eldridge, RR; Tennis, P, 2002) |
| "This study was designed to evaluate the effects of pregnancy on the kinetics of lamotrigine (LTG)." | 7.70 | Effects of pregnancy on the pharmacokinetics of lamotrigine in dogs. ( Al-Hassan, MI; Bawazir, SA; Matar, KM; Nicholls, PJ; Tekle, A, 1999) |
| "To examine the safety of lamotrigine (LTG) used in general practice to treat epilepsy." | 7.69 | Safety of long-term lamotrigine in epilepsy. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1997) |
| "We investigated the effect of pregnancy on the kinetics of lamotrigine (LTG), passage of LTG over the placenta and the excretion of the drug in breast milk." | 7.69 | Lamotrigine in pregnancy and lactation: a case report. ( Ohman, I; Tomson, T; Vitols, S, 1997) |
| "The high risk of bipolar depression during pregnancy encourages consideration of lamotrigine (LTG)." | 6.73 | Lamotrigine in bipolar disorder: efficacy during pregnancy. ( Baldessarini, RJ; Calamaras, MR; Juric, S; Knight, B; Newport, DJ; Pennell, PB; Stowe, ZN; Viguera, AC, 2008) |
| "Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser." | 6.49 | Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons? ( Dodd, S; Horgan, D; Vajda, FJ, 2013) |
| "Lamotrigine is a sodium-channel-modulating, antiepileptic drug (AED), which was approved in the USA in 1994 for use in partial-onset seizures." | 6.48 | Lamotrigine use in pregnancy. ( Aggarwal, P; Moore, JL, 2012) |
| "Lamotrigine is an anti-epileptic agent with broad efficacy." | 6.42 | Review of lamotrigine and its clinical applications in epilepsy. ( Choi, H; Morrell, MJ, 2003) |
| " The most common adverse event with lamotrigine was headache." | 6.42 | Safety and tolerability of lamotrigine for bipolar disorder. ( Asnis, GM; Bentley, B; Bowden, CL; Ginsberg, LD; Leadbetter, R; White, R, 2004) |
| "Epilepsy treatment during pregnancy is still challenging." | 5.72 | Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy? ( Castelli, A; Del Bianco, C; Izzi, F; Liguori, C; Manfredi, N; Mari, L; Mercuri, NB; Placidi, F; Romigi, A; Tombini, M; Ulivi, M, 2022) |
| "Pregnancy is a state where drug pharmacokinetic changes are more pronounced and more rapid than any other period of life." | 5.48 | Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats. ( Keramati, K; Mahdavi, A; Moezifar, M; Narenji Sani, R; Saberi, N, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 5.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| " In case of breakthrough seizures or increased seizure frequency, dosage adjustment of both drugs may be required." | 5.36 | Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. ( de Haan, GJ; Edelbroek, P; Lindhout, D; Sander, JW; Wegner, I, 2010) |
| "Lamotrigine (LTG) has been used in epilepsia patients for treatment of partial seizures." | 5.35 | Unilateral radius aplasia due to lamotrigine and oxcarbazepine use in pregnancy. ( Cetinkaya, M; Köksal, N; Ozkan, H, 2008) |
| "Pregnant women with epilepsy on one or more of the following AEDs: lamotrigine, carbamazepine, phenytoin or levetiracetam." | 5.27 | AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. ( Bagary, M; Coleman, J; D'Amico, M; Denny, E; Dodds, J; Eldridge, S; Greenhill, L; Hard, K; Kelso, A; Khan, KS; Marlin, N; McCorry, D; Middleton, L; Moss, N; Newton, S; Pirie, A; Pullen, A; Rikunenko, R; Roberts, T; Rogozińska, E; Thangaratinam, S; Weckesser, A, 2018) |
| "12) when compared to those following lamotrigine (LTG) exposure during pregnancy (3 studies [n = 591])." | 5.22 | Adverse fetal and neonatal outcomes following in-utero exposure to oxcarbazepine: A systematic review and meta-analysis. ( Ahmad, S; Athar, F; Cheema, HA; Ehsan, M; Farooq, M; Lo, KB; Naveed, A; Umer, M, 2022) |
| "Lamotrigine is the most widely used anti-epileptic drug in pregnancy because of its low teratogenicity." | 5.22 | Dosage Optimization of Lamotrigine in Pregnancy: A Pharmacometric Approach Using Modeling and Simulation. ( G, SS; Kp, A; Pa, B; Thomas, G, 2022) |
| "In this prospective, observational, assessor-masked, multicentre study, we enrolled pregnant women with epilepsy on antiepileptic drug monotherapy (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, at 25 epilepsy centres in the UK and the USA." | 5.17 | Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. ( Baker, GA; Bromley, RL; Browning, N; Clayton-Smith, J; Cohen, MJ; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2013) |
| "To prospectively analyse the pharmacokinetics of lamotrigine (LTG) during pregnancy and lactation in a consecutive series of epileptic pregnant women." | 5.14 | Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. ( Bauer, S; Dudenhausen, JW; Fotopoulou, C; Henrich, W; Kretz, R; Schefold, JC; Schmitz, B, 2009) |
| " This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin, carbamazepine, phenobarbital, and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy." | 5.12 | Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications. ( Demir, O; Kaplan, YC, 2021) |
| "In eight women treated with lamotrigine monotherapy, the lamotrigine dose/plasma concentration (D/C) ratio increased by 295% from baseline outside pregnancy to midgestation, whereas in six women treated with lamotrigine in combination with valproate, the increase was only 60%." | 5.12 | Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. ( Luef, G; Ohman, I; Pittschieler, S; Sabers, A; Tomson, T, 2006) |
| "This paper reviewed the relevant literature on the effects of lamotrigine on pregnancy outcomes to provide useful information regarding lamotrigine use in pregnant women with bipolar disorder." | 4.98 | The risks associated with the use of lamotrigine during pregnancy. ( Gao, Z; Kong, L; Wang, B; Wang, C; Zhou, T, 2018) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 4.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| " Oxcarbazepine and lamotrigine were associated with increased occurrence of autism." | 4.95 | Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. ( Cogo, E; D'Souza, J; Finkelstein, Y; Hemmelgarn, BR; Hutton, B; Kealey, R; MacDonald, H; Reynen, E; Rios, P; Soobiah, C; Straus, SE; Thavorn, K; Tricco, AC; Veroniki, AA; Yazdi, F, 2017) |
| "We searched MEDLINE (1966-2012), EMBASE (1980-2012) and Cochrane, for relevant citations on the effectiveness of different monitoring strategies on seizure deterioration in pregnant women with epilepsy on lamotrigine." | 4.90 | Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis. ( Al Wattar, BH; Bagary, M; Doug, M; Greenhill, L; Houston, V; Khan, KS; McCorry, D; Pirie, AM; Pirie, DA; Siddiqua, A; Thangaratinam, S, 2014) |
| "The International Lamotrigine Pregnancy Registry monitored for a signal of a substantial increase in the frequency of major congenital malformations associated with lamotrigine exposures in pregnancy over an 18-year period." | 4.90 | Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry. ( Cragan, J; Cunnington, M; Lowensohn, R; Messenheimer, J; Sinclair, S; Tennis, P; Weil, J; Yerby, M, 2014) |
| "The paper presents the review of literature on the age aspect of using lamotrigine in pubertal period, in women of reproductive age, during pregnancy and lactation and in climacteric period." | 4.87 | [Lamotrigine in treatment of women with epilepsy]. ( Agranovich, OV; Dranko, DV; Vlasov, PN, 2011) |
| "A systematic search was carried out of electronic databases, reference books and other sources for original research studies which examined the effects of commonly used mood stabilizers (sodium valproate, carbamazepine, lamotrigine and lithium carbonate) on pregnancy outcomes." | 4.86 | Mood stabilizers in pregnancy: a systematic review. ( Buist, A; Galbally, M; Roberts, M, 2010) |
| "Studies have confirmed that the elimination of lamotrigine and the active metabolite of oxcarbazepine is enhanced during pregnancy." | 4.85 | Managing antiepileptic drugs during pregnancy and lactation. ( Sabers, A; Tomson, T, 2009) |
| " We present three cases of women exposed to lamotrigine during pregnancy and breastfeeding, with follow up of their infants until 15-18 months of development." | 4.85 | Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. ( Epperson, CN; Gonzalez, J; Kim, DR; O'Reardon, JP; Wakil, L, 2009) |
| "To provide an overview of the available literature concerning the prevention of congenital malformations following the use of lamotrigine (LMT) during pregnancy." | 4.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| "To investigate whether children born to mothers who used carbamazepine during pregnancy had worse academic performance in adolescence." | 4.31 | Prenatal Carbamazepine Exposure and Academic Performance in Adolescents: A Population-Based Cohort Study. ( Lee, PMY; Li, F; Li, J; Ren, T, 2023) |
| "Findings from this explorative study strengthen the evidence for the warning against the use of valproate in pregnancy and raise concern of risks of specific psychiatric disorders associated with topiramate and levetiracetam." | 4.31 | Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. ( Alvestad, S; Bjørk, MH; Christensen, J; Cohen, JM; Dreier, JW; Furu, K; Gissler, M; Igland, J; Leinonen, MK; Sun, Y; Tomson, T; Zoega, H, 2023) |
| "Despite widespread monotherapy use of lamotrigine or levetiracetam during pregnancy, prospectively collected, blinded child development data are still limited." | 4.31 | Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study. ( Bromley, RL; Bullen, P; Campbell, E; Clayton-Smith, J; Craig, J; García-Fiñana, M; Hughes, DM; Ingham, A; Irwin, B; Jackson, C; Kelly, T; Morrow, J; Rushton, S; Winterbottom, J; Wood, A; Yates, LM, 2023) |
| "Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy." | 4.31 | Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. ( Barry, JM; Birnbaum, AK; French, JA; Harden, CL; Karanam, A; Pennell, PB, 2023) |
| "Use of valproate and carbamazepine decreased progressively, use of lamotrigine remained relatively static, and the use of levetiracetam increased progressively, whereas the use of topiramate first increased and then fell again, associated with a temporary increase in malformation-associated pregnancy rate." | 4.31 | Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control. ( Eadie, M; Graham, J; Hitchcock, A; Lander, C; O'Brien, T; Perucca, P; Vajda, F, 2023) |
| " In our case series, lamotrigine proved to be less effective and less controllable than other drugs during pregnancy." | 4.12 | [Women with epilepsy before and during pregnancy: a case series of outpatient counseling in a tertiary epilepsy center]. ( Bien, CG; Hagemann, A; Knaak, N; Müffelmann, B, 2022) |
| "Exposure to lamotrigine in breastfed newborns is lower than exposure during pregnancy." | 4.12 | Monitoring of lamotrigine concentrations in mothers, colostrum, and breastfed newborns during the early postpartum period. ( Brozmanova, H; Grundmann, M; Kacirova, I, 2022) |
| "1%) received an anti-epileptic medication during pregnancy of which more than half received lamotrigine or levetiracetam." | 4.12 | Use of antiepileptic drugs by trimester. ( Benson, RJ; D'Alton, ME; Friedman, AM; Huang, Y; Logue, TC; Pack, AM; Wright, JD, 2022) |
| " Our results suggest an association between disabling seizure occurrence during pregnancy and lamotrigine usage in polytherapy that warrants further evaluation." | 4.12 | Epilepsy and Pregnancy: An Audit of Specialized Care. ( Li, J; Nguyen, DK; Toffa, DH, 2022) |
| "During pregnancy, various physiological changes occur that can alter the pharmacokinetics of antiepileptic drugs, such as lamotrigine (LTG)." | 4.02 | Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. ( Cao, YF; Guo, Y; Sun, XY; Tao, YY; Wang, ML; Wang, ZY; Zhao, L, 2021) |
| "This study was carried out to determine changes over time in use of folic acid, anti-epileptic drugs (AED), seizures during pregnancy and malformation rate over two decades in women with epilepsy enrolled in the Kerala registry of Epilepsy and Pregnancy (KREP)." | 3.96 | Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. ( A S, R; Baishya, J; Jose, M; Keni, RR; Sankara Sarma, P; Thomas, SV, 2020) |
| "The aim of the study was to assess whether, male patients with epilepsy, switching from valproic acid (VPA) to levetiracetam (LEV) or lamotrigine (LMG) critically improves sperm counts and parameters, increasing chance of patients' female partners to spontaneously conceive." | 3.96 | An open study of valproate in subfertile men with epilepsy. ( Georgiou, I; Kostoulas, C; Markoula, S; Siarava, E; Zikopoulos, A, 2020) |
| "Lamotrigine has become the most frequently prescribed drug in the treatment of pregnant women with epilepsy." | 3.91 | A Short Communication: Lamotrigine Levels in Milk, Mothers, and Breastfed Infants During the First Postnatal Month. ( Brozmanova, H; Grundmann, M; Kacirova, I, 2019) |
| "To evaluate the pharmacokinetic changes in lamotrigine (LTG) from prepregnancy to postpartum and to assess the impact of therapeutic drug monitoring (TDM) on seizure management during pregnancy in a Chinese population." | 3.91 | Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. ( Ding, Y; Guo, Y; Tan, X; Zhang, S, 2019) |
| "The study included the children of 83 epileptic women treated with lamotrigine during pregnancy, at a tertiary medical centre between 2004-2014." | 3.88 | Short- and long-term complications of in utero exposure to lamotrigine. ( Berger, I; Cohen-Israel, M; Klinger, G; Linder, N; Martonovich, EY; Stahl, B, 2018) |
| " This limitation and high risks of neural tube and other major teratogenic effects, especially of valproate, indicate the need for great caution in the use of valproate and carbamazepine to treat bipolar disorder in women of child-bearing age." | 3.88 | Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary. ( Baldessarini, RJ; Patel, N; Viguera, AC, 2018) |
| "To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications." | 3.88 | Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Pennell, PB, 2018) |
| "To evaluate the impact of maternal UGT1A4 and UGT2B7 genetic polymorphisms and sex of foetus on gestation-induced changes in lamotrigine (LTG) clearance during pregnancy and post-partum (PP)." | 3.88 | UGT polymorphisms and lamotrigine clearance during pregnancy. ( Ekström, L; Hansen, TF; Öhman, I; Petrenaite, V; Sabers, A; Sæbye, D; Tomson, T, 2018) |
| "To determine how early lamotrigine clearance (LTG-CL/F) increases during early pregnancy in women with epilepsy and to quantify the relationship of LTG-CL/F to estradiol concentrations and gestational week." | 3.88 | Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age. ( Allien, S; Barnard, S; Birnbaum, AK; Callisto, SP; French, JA; Harden, CL; Karanam, A; Lau, C; Pennell, PB, 2018) |
| " Among all mood stabilizers, lithium has the largest evidence base for efficacy in the peripartum period, but lamotrigine is increasingly prescribed for bipolar spectrum disorders during pregnancy." | 3.85 | Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: A population-based cohort study. ( Bergink, V; Clark, CT; Kushner, SA; Liu, X; Munk-Olsen, T; Wesseloo, R, 2017) |
| "Callers who contacted the Israeli Teratology Information Service regarding lamotrigine treatment or NTE during pregnancy between 1997 and 2008 were prospectively followed-up." | 3.85 | Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. ( Diav-Citrin, O; Finkel-Pekarsky, V; Ornoy, A; Shechtman, S; Zvi, N, 2017) |
| "Here, we present the outcomes in the subset of six women who were treated with lamotrigine 100-400 mg/day for the entire pregnancy." | 3.83 | Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand. ( Hatters-Friedman, S; Moller-Olsen, C; North, A; Prakash, C, 2016) |
| " Here we provide updated results from the UK Epilepsy and Pregnancy Register of the risk of MCMs after monotherapy exposure to valproate, carbamazepine and lamotrigine." | 3.80 | Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. ( Campbell, E; Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Kennedy, F; Liggan, B; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2014) |
| "To assess the effectiveness of the newer antiepileptic drugs (AEDs)-in particular lamotrigine, topiramate, and levetiracetam-in controlling epileptic seizures in pregnant women." | 3.80 | The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy. ( Eadie, M; Graham, J; Lander, C; O'Brien, T; Vajda, FJ, 2014) |
| "Evidence from this and other studies suggests that lamotrigine and levetiracetam have low risk for teratogenesis, but that topiramate exposure early in pregnancy may be associated with dose-related anatomical teratogenesis, as valproate is already known to be." | 3.80 | The teratogenicity of the newer antiepileptic drugs - an update. ( Eadie, MJ; Graham, J; Lander, CM; O'Brien, TJ; Vajda, FJ, 2014) |
| "To analyze seizure control, dose adjustments, and other changes of antiepileptic drug (AED) treatment during pregnancy in a large cohort of women with epilepsy entering pregnancy on monotherapy with carbamazepine, lamotrigine, phenobarbital, or valproate." | 3.79 | Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Tomson, T; Vajda, F, 2013) |
| "Little information is available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder." | 3.79 | Lamotrigine dosing for pregnant patients with bipolar disorder. ( Clark, CT; Helsel, J; Klein, AM; Perel, JM; Wisner, KL, 2013) |
| "Treatment with lamotrigine (LTG) during pregnancy is associated with a pronounced risk of seizure deterioration, because pregnancy accelerates LTG elimination." | 3.78 | Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. ( Sabers, A, 2012) |
| "Lamotrigine is an anticonvulsant and has an antiglutamatergic action, which may contribute to its antidepressant effects, since glutamate has been linked to depression." | 3.78 | Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats. ( Abelaira, HM; Cipriano, AL; Quevedo, J; Réus, GZ; Ribeiro, KF; Scaini, G; Streck, EL; Zappellini, G, 2012) |
| "Based on epidemiological data it is advised to whenever possible avoid valproic acid during pregnancy." | 3.78 | Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes. ( Boersma, C; de Jong-van den Berg, LT; Jentink, J; Postma, MJ, 2012) |
| " The antiepileptic drug lamotrigine (LTG) is a UGT1A4-substrate, and its serum concentration falls by over 50% during pregnancy, leading to impaired seizure control." | 3.77 | Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term. ( Reimers, A; Stuen, I; Sundby, E; Østby, L, 2011) |
| "To investigate the physiological mechanisms behind the pronounced decline of lamotrigine (LTG) serum concentrations during pregnancy." | 3.77 | Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. ( Bråthen, G; Brodtkorb, E; Helde, G; Reimers, A, 2011) |
| "Health care providers reported lamotrigine exposure during pregnancy, and subsequent outcomes, on a voluntary basis." | 3.77 | Final results from 18 years of the International Lamotrigine Pregnancy Registry. ( Cunnington, MC; Ferber, S; Messenheimer, JA; Tennis, P; Weil, JG; Yerby, M, 2011) |
| "To determine the frequency of malformations among infants born to women who had taken lamotrigine or carbamazepine as part of polytherapy during the first trimester of pregnancy." | 3.77 | Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. ( Hernandez-Diaz, S; Holmes, LB; Mittendorf, R; Shen, A; Smith, CR, 2011) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 3.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| " Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single AED (carbamazepine, lamotrigine, phenytoin, or valproate)." | 3.76 | Effects of breastfeeding in children of women taking antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2010) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 3.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single antiepileptic agent (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective, observational, multicenter study in the United States and the United Kingdom." | 3.75 | Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2009) |
| "Previous studies have demonstrated that the pharmacokinetics of the new antiepileptic drug (AED) lamotrigine (LTG) are substantially influenced by pregnancy and are more likely to be associated with seizure deterioration in pregnancy compared to other AEDs." | 3.75 | Seizure frequency in pregnant women treated with lamotrigine monotherapy. ( Petrenaite, V; Sabers, A, 2009) |
| "Lamotrigine is frequently used to manage epilepsy during pregnancy." | 3.75 | Lamotrigine and twin pregnancy, incidental event or possible correlation? ( Azimi, AR; Karvigh, SA; Motamedi, M; Navardi, S; Sahraian, MA, 2009) |
| "To report a case of severe apnea in an infant exposed to lamotrigine through breast-feeding." | 3.75 | Severe apnea in an infant exposed to lamotrigine in breast milk. ( Aronsen, L; Nordmo, E; Småbrekke, L; Vorren, S; Wasland, K, 2009) |
| "This substudy of the Neurodevelopmental Effects of Antiepileptic Drugs investigation enrolled pregnant women with epilepsy on AED monotherapy (carbamazepine, lamotrigine, and valproate)." | 3.75 | A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. ( Gaillard, WD; McVearry, KM; Meador, KJ; VanMeter, J, 2009) |
| "(1) Numerous follow-up studies of pregnancies in women with epilepsy show that valproic acid is more teratogenic than other antiepileptics." | 3.75 | Valproic acid: long-term effects on children exposed in utero. ( , 2009) |
| "We prospectively surveyed 23 pregnant women with epilepsy on lamotrigine monotherapy and reported outcome of their pregnancies, including one fetal intrauterine death, one spontaneous abortion and two preterm deliveries." | 3.75 | Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy--aspects of pre-pregnancy counseling and drug monitoring. ( Bakulić, TI; Bosnjak-Pasić, M; Cvitanović-Sojat, L; Demarin, V; Fucić, A; Gjergja-Juraski, R; Mikula, I; Miskov, S, 2009) |
| "Data from the International Lamotrigine Pregnancy Registry were analyzed to examine the effect of maximal first-trimester maternal dose of lamotrigine monotherapy on the risk of major birth defects (MBDs)." | 3.74 | Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. ( Cunnington, M; Ferber, S; Quartey, G, 2007) |
| "We describe the case of a pregnancy healthy outcome after in utero consecutive exposure to lamotrigine and citalopram." | 3.74 | Consecutive exposure to lamotrigine and citalopram during pregnancy. ( Gentile, S; Vozzi, F, 2007) |
| "One of my female patients has epilepsy and is currently receiving lamotrigine monotherapy." | 3.74 | Teratogenicity of lamotrigine. ( Koren, G; Nulman, I; Shor, S, 2007) |
| "To characterize the magnitude and course of alterations in total and free lamotrigine (LTG) clearance (Cl) during pregnancy and the postpartum period, to assess the impact of therapeutic drug monitoring (TDM) on seizure frequency, to determine the ratio to individual target LTG concentration that is associated with increased seizure risk, and to evaluate maternal postpartum toxicity." | 3.74 | Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. ( Holley, DK; Koganti, A; Newman, M; Newport, DJ; Peng, L; Pennell, PB; Ritchie, JC; Stowe, ZN, 2008) |
| "To further characterize pregnancy-induced alterations in the pharmacokinetics of lamotrigine (LTG)." | 3.74 | Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. ( Beck, O; Ohman, I; Tomson, T; Vitols, S, 2008) |
| "The infant exposed in the first trimester of pregnancy to the anticonvulsant drug lamotrigine has an increased risk to have an isolated cleft palate or cleft lip deformity." | 3.74 | Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. ( Baldwin, EJ; Glassman, L; Habecker, E; Holmes, LB; Smith, CR; Wong, SL; Wyszynski, DF, 2008) |
| "To report the frequency of major malformations in lamotrigine-exposed pregnancies from September 1, 1992, through March 31, 2004, in the International Lamotrigine Pregnancy Registry." | 3.73 | Lamotrigine and the risk of malformations in pregnancy. ( Cunnington, M; Tennis, P, 2005) |
| "During her first pregnancy, a 37-year-old woman with idiopathic generalised epilepsy that was adequately controlled with lamotrigine experienced a series of epileptic seizures following an elective caesarean section." | 3.73 | [Epileptic seizures during childbirth in a patient with idiopathic generalised epilepsy]. ( Bloem, BR; Renier, WO; Voermans, NC; Zwarts, MJ, 2005) |
| " Plasma homocysteine, folate, vitamins B12 and B6 (pyridoxal phosphate), and red cell folate levels were measured in samples while she was receiving folic acid therapy for 1 month during the second trimester of pregnancy." | 3.73 | Antiepileptic drugs: a case report in a pregnancy with a neural tube defect. ( Bongain, A; Candito, M; Guéant, JL; Naimi, M; Van Obberghen, E, 2006) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 3.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| "This study was performed to clarify alterations in lamotrigine (LTG) clearance during pregnancy and childbirth." | 3.72 | The impact of pregnancy and childbirth on the metabolism of lamotrigine. ( Helmers, SL; Henry, TR; Montgomery, JQ; Newport, DJ; Pennell, PB; Stowe, ZN, 2004) |
| "Many women with epilepsy who are planning a pregnancy are treated with lamotrigine (LTG), resulting in greater fetal exposure to the drug." | 3.72 | Concerns regarding lamotrigine and breast-feeding. ( D'Abreu, A; Kao, A; Liporace, J, 2004) |
| "The authors describe 12 pregnancies in women with epilepsy using lamotrigine (LTG) monotherapy." | 3.72 | Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. ( Augustijn, P; de Haan, GJ; Dévilé-Notschaele, M; Edelbroek, P; Engelsman, M; Lindhout, D; Segers, J, 2004) |
| "several parameters, concerning fertility were measured in 40 albino male rats of Sprague Dawley strain, they were divided into 4 groups, group one received vehicle (distilled water), group two received Vigabatrin in a dose of 200 mg/kg body weight, group three received Lamotrigine in a dose of 30 mg/kg body weight, and group four received Gabapentin 100 mg/kg body weight." | 3.72 | The effect of Vigabatrin, Lamotrigine and Gabapentin on the fertility, weights, sex hormones and biochemical profiles of male rats. ( Abdul-Zahra, E; Bataineh, H; Daoud, AS; Otoom, S, 2004) |
| "To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy." | 3.71 | Lamotrigine clearance during pregnancy. ( Blesi, K; Leppik, IE; Remmel, R; Sathanandan, ST; Tran, TA, 2002) |
| "In 1992, the International Lamotrigine Pregnancy Registry was initiated to enroll prospectively and to monitor pregnancies exposed to lamotrigine (LTG) for the occurrence of major birth defects." | 3.71 | Preliminary results on pregnancy outcomes in women using lamotrigine. ( Eldridge, RR; Tennis, P, 2002) |
| " In the last decade, pregnancy registries have been activated by collaborative groups of physicians in Europe (EURAP), North America (NAREP), Australia and India (the latter two recently merged into EURAP), to enroll a large number of exposed women to be monitored prospectively with standardized methods, and by three pharmaceutical companies marketing lamotrigine, gabapentin and vigabatrin, as part of their post-marketing surveillance." | 3.71 | Pregnancy registries in epilepsy. ( Annegers, JF; Beghi, E, 2001) |
| " The proportions of outcomes with birth defects are as follows: in the Acyclovir (antiviral medication) Pregnancy Registry (1984-1998) (19/581), 3." | 3.70 | Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. ( Andrews, EB; Ephross, SA; Heffner, CR; Reiff-Eldridge, R; Tennis, PS; White, AD, 2000) |
| "To investigate the transfer of lamotrigine in pregnancy and during lactation from a mother on lamotrigine treatment to her child." | 3.69 | Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. ( Jürgens, U; Kurlemann, G; May, TW; Rambeck, B; Stodieck, SR, 1997) |
| "To examine the safety of lamotrigine (LTG) used in general practice to treat epilepsy." | 3.69 | Safety of long-term lamotrigine in epilepsy. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1997) |
| "We investigated the effect of pregnancy on the kinetics of lamotrigine (LTG), passage of LTG over the placenta and the excretion of the drug in breast milk." | 3.69 | Lamotrigine in pregnancy and lactation: a case report. ( Ohman, I; Tomson, T; Vitols, S, 1997) |
| "The high risk of bipolar depression during pregnancy encourages consideration of lamotrigine (LTG)." | 2.73 | Lamotrigine in bipolar disorder: efficacy during pregnancy. ( Baldessarini, RJ; Calamaras, MR; Juric, S; Knight, B; Newport, DJ; Pennell, PB; Stowe, ZN; Viguera, AC, 2008) |
| " Exposure to certain newer ASMs, such as lamotrigine and levetiracetam, does not thus far appear to impact certain aspects of neurodevelopment, but further delineation across the different neurodevelopmental domains and dosage levels is required." | 2.72 | Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review. ( Bromley, RL; Knight, R; Wittkowski, A, 2021) |
| "Epilepsy is one of the most common neurological complications in pregnancy; some women continue to use antiepileptic drugs (AEDs) to control seizures." | 2.66 | [Transfer Mechanisms of Compounds between Mother and Fetus/Infant Aimed for Optimized Medication during Pregnancy and Breastfeeding]. ( Furugen, A, 2020) |
| " For optimal dosing in pregnancy, therapeutic drug monitoring may be required to maintain effective drug concentrations." | 2.58 | Treatment of Peripartum Bipolar Disorder. ( Clark, CT; Wisner, KL, 2018) |
| "Lamotrigine was preferred in patients with co-morbid depression." | 2.55 | Epilepsy treatment in adults and adolescents: Expert opinion, 2016. ( Chimato, N; Frank, RD; Karceski, SC; Shih, JJ; Vargas, E; Whitlock, JB, 2017) |
| "Epilepsy affects fetal brain development during gestation in pregnant rats, therefore anti-epileptic therapy should be continued during pregnancy." | 2.53 | Effects of phenytoin and lamotrigine treatment on serum BDNF levels in offsprings of epileptic rats. ( Doğan, Z; Kamışlı, Ö; Soysal, H, 2016) |
| "Lamotrigine is a safe anti-epileptic drug among pregnant and lactating women." | 2.52 | Lamotrigine effects on breastfed infants. ( Asgarzadeh, L; Dalili, H; Nayeri, F; Shariat, M, 2015) |
| "Pharmacotherapy for mood disorders during pregnancy is often complicated by pregnancy-related pharmacokinetic changes and the need for dose adjustments." | 2.50 | Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. ( Byatt, N; Deligiannidis, KM; Freeman, MP, 2014) |
| "Seizures and intracranial hemorrhage are possible medical diseases that any obstetrician may encounter." | 2.49 | Seizures and intracranial hemorrhage. ( Alexander, JM; Wilson, KL, 2013) |
| "Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser." | 2.49 | Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons? ( Dodd, S; Horgan, D; Vajda, FJ, 2013) |
| "Lamotrigine is a sodium-channel-modulating, antiepileptic drug (AED), which was approved in the USA in 1994 for use in partial-onset seizures." | 2.48 | Lamotrigine use in pregnancy. ( Aggarwal, P; Moore, JL, 2012) |
| "Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures." | 2.45 | The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? ( Abou-Khalil, B; Montouris, G, 2009) |
| "Lamotrigine is an antiepileptic drug that stabilizes neural membranes by blocking the activation of voltage-sensitive sodium channels and inhibiting the presynaptic release of glutamate." | 2.43 | Lamotrigine for neuropathic pain. ( Eisenberg, E; Krivoy, N; Shifrin, A, 2005) |
| "Lamotrigine is an anti-epileptic agent with broad efficacy." | 2.42 | Review of lamotrigine and its clinical applications in epilepsy. ( Choi, H; Morrell, MJ, 2003) |
| " Future studies of formal pharmacokinetic modeling of AEDs during pregnancy and the postpartum period could provide an important step toward achieving effective drug dosing to maintain therapeutic objectives for the mother but, at the same time, to minimize fetal drug exposure." | 2.42 | Antiepileptic drug pharmacokinetics during pregnancy and lactation. ( Pennell, PB, 2003) |
| " The most common adverse event with lamotrigine was headache." | 2.42 | Safety and tolerability of lamotrigine for bipolar disorder. ( Asnis, GM; Bentley, B; Bowden, CL; Ginsberg, LD; Leadbetter, R; White, R, 2004) |
| " By November 1992 about 5,800 patient-years' experience of adverse effects had been compiled." | 2.39 | Safety of lamotrigine. ( Richens, A, 1994) |
| "Forty patients (39." | 1.91 | Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. ( Barambio, S; Becerra, JL; Chíes, E; Ciurans, J; Codina, M; Fumanal, A; García-Esperón, C; Grau-López, L; Jiménez, M, 2023) |
| "Seizures were classified into two categories: tonic‒clonic/focal to bilateral tonic‒clonic seizures and non-tonic‒clonic seizures." | 1.91 | Changes in seizure frequency and anti-seizure medication therapy during pregnancy and one year postpregnancy. ( Du, Y; Fang, W; Gong, J; Huang, W; Wang, X; Xia, N; Xu, H; Xu, Q; Zheng, R; Zhu, Z, 2023) |
| "Epilepsy is one of the most common neurologic unit diseases that have different prevalence in different parts of the world." | 1.72 | Evaluation of family planning methods in married women with epilepsy. ( Avan, R; Ershadi, F; Mousavi Mirzaei, SM; Roshanravan, B; Sahebnasagh, A; Tabrizi, N, 2022) |
| "Planned pregnancy was the only independent factor significantly associated with decreased risk of adverse pregnancy outcomes (OR, 0." | 1.72 | Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China. ( Jiang, W; Jiang, Y; Ma, L; Shi, X; Song, C; Wang, Y; Xia, L; Zhang, Y; Zhao, J, 2022) |
| "To study the risk of intellectual disability and delayed development in childhood milestones among children of women who used valproate or other AEDs during pregnancy." | 1.56 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. ( Christensen, J; Daugaard, CA; Dreier, JW; Pedersen, L; Sun, Y, 2020) |
| "The mean daily dosage of lamotrigine was 351." | 1.51 | Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. ( Augustin, M; Franz, C; Gründer, G; Paulzen, M; Saßmannshausen, H; Schoretsanitis, G; Stingl, JC, 2019) |
| "Pregnancy is a state where drug pharmacokinetic changes are more pronounced and more rapid than any other period of life." | 1.48 | Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats. ( Keramati, K; Mahdavi, A; Moezifar, M; Narenji Sani, R; Saberi, N, 2018) |
| "Evidence for the comparative teratogenic risk of antiepileptic drugs is insufficient, particularly in relation to the dosage used." | 1.48 | Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 1.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "Causes of brain abscesses are multiple and often unclear." | 1.37 | Cerebral abscess due to an abnormal drainage of the superior vena cava. ( Alamowitch, S; Hammoudi, N; Khalil, A; Muresan, IP; Yger, M, 2011) |
| " In case of breakthrough seizures or increased seizure frequency, dosage adjustment of both drugs may be required." | 1.36 | Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. ( de Haan, GJ; Edelbroek, P; Lindhout, D; Sander, JW; Wegner, I, 2010) |
| "Lamotrigine (LTG) has been used in epilepsia patients for treatment of partial seizures." | 1.35 | Unilateral radius aplasia due to lamotrigine and oxcarbazepine use in pregnancy. ( Cetinkaya, M; Köksal, N; Ozkan, H, 2008) |
| "We believe that the neonatal seizures were caused by lamotrigin withdrawal." | 1.35 | [Neonatal seizures caused by lamotrigin withdrawal?]. ( Längler, A; Thiel, M; Vieker, S, 2009) |
| " The number or dosage of AEDs were more often increased in pregnancies with seizures (OR: 3." | 1.33 | Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. ( , 2006) |
| "Lamotrigine is an antiepileptic drug with a low adverse-effect profile." | 1.33 | Maternal lamotrigine treatment and elevated neonatal gamma-glutamyl transpeptidase. ( Dubnov-Raz, G; Merlob, P; Shapiro, R, 2006) |
| "The incidence of birth defects in relation to specific AEDs was: valproate (16." | 1.32 | The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. ( Graham, J; Hitchcock, A; Lander, C; O'Brien, TJ; Vajda, FJ, 2003) |
| "at high doses can induce intrauterine growth retardation and at low multiple doses causes a dose-dependent increase in embryonic resorption, craniofacial and caudal malformations as well as maternal toxicity in the mouse." | 1.32 | Experimental studies on reproductive toxicologic effects of lamotrigine in mice. ( Abdulrazzaq, YM; Bastaki, SM; Chandranath, SI; Padmanabhan, R; Shafiullah, M, 2003) |
| " The dosage levels studied corresponded to four times the median effective dose (ED50) in rats." | 1.31 | Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study. ( Azoubel, R; Marchi, NS; Tognola, WA, 2001) |
| "Juvenile myoclonic epilepsy is a relatively common, though under diagnosed, form of epilepsy that commences in adolescence." | 1.29 | Juvenile myoclonic epilepsy. ( Buchanan, N, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (4.09) | 18.2507 |
| 2000's | 80 (36.36) | 29.6817 |
| 2010's | 89 (40.45) | 24.3611 |
| 2020's | 42 (19.09) | 2.80 |
| Authors | Studies |
|---|---|
| Mari, L | 1 |
| Placidi, F | 1 |
| Romigi, A | 1 |
| Tombini, M | 1 |
| Del Bianco, C | 1 |
| Ulivi, M | 1 |
| Liguori, C | 1 |
| Manfredi, N | 1 |
| Castelli, A | 1 |
| Mercuri, NB | 1 |
| Izzi, F | 1 |
| Müffelmann, B | 1 |
| Hagemann, A | 1 |
| Knaak, N | 1 |
| Bien, CG | 1 |
| Pennell, PB | 15 |
| Karanam, A | 3 |
| Meador, KJ | 10 |
| Gerard, E | 1 |
| Kalayjian, L | 1 |
| Penovich, P | 3 |
| Matthews, A | 1 |
| McElrath, TM | 1 |
| Birnbaum, AK | 3 |
| Ershadi, F | 1 |
| Mousavi Mirzaei, SM | 1 |
| Tabrizi, N | 1 |
| Roshanravan, B | 1 |
| Sahebnasagh, A | 1 |
| Avan, R | 1 |
| Kikuchi, D | 1 |
| Obara, T | 1 |
| Miura, R | 1 |
| Suzuki, N | 1 |
| Josaka, R | 1 |
| Tokunaga, M | 1 |
| Ouchi, R | 1 |
| Usui, K | 1 |
| Okada, K | 1 |
| Athar, F | 1 |
| Ehsan, M | 1 |
| Farooq, M | 1 |
| Lo, KB | 1 |
| Cheema, HA | 1 |
| Ahmad, S | 1 |
| Naveed, A | 1 |
| Umer, M | 1 |
| Kacirova, I | 3 |
| Grundmann, M | 3 |
| Brozmanova, H | 3 |
| Bjørk, MH | 5 |
| Zoega, H | 5 |
| Leinonen, MK | 5 |
| Cohen, JM | 7 |
| Dreier, JW | 4 |
| Furu, K | 5 |
| Gilhus, NE | 1 |
| Gissler, M | 5 |
| Hálfdánarson, Ó | 1 |
| Igland, J | 2 |
| Sun, Y | 4 |
| Tomson, T | 20 |
| Alvestad, S | 5 |
| Christensen, J | 6 |
| Pa, B | 1 |
| G, SS | 1 |
| Thomas, G | 1 |
| Kp, A | 1 |
| Logue, TC | 1 |
| Huang, Y | 1 |
| Benson, RJ | 1 |
| Pack, AM | 1 |
| Wright, JD | 1 |
| D'Alton, ME | 1 |
| Friedman, AM | 1 |
| Shi, X | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Song, C | 1 |
| Jiang, Y | 1 |
| Zhao, J | 1 |
| Xia, L | 1 |
| Ma, L | 1 |
| Jiang, W | 1 |
| Jiménez, M | 1 |
| Grau-López, L | 1 |
| Ciurans, J | 1 |
| García-Esperón, C | 1 |
| Fumanal, A | 1 |
| Barambio, S | 1 |
| Chíes, E | 1 |
| Codina, M | 1 |
| Becerra, JL | 1 |
| Ren, T | 1 |
| Lee, PMY | 1 |
| Li, F | 1 |
| Li, J | 3 |
| Lyons, JG | 1 |
| Suarez, EA | 1 |
| Fazio-Eynullayeva, E | 1 |
| Maro, JC | 1 |
| Corey, C | 1 |
| Toh, S | 1 |
| Shinde, MU | 1 |
| Cesta, CE | 3 |
| Nørgaard, M | 3 |
| Einarsdóttir, K | 3 |
| Engeland, A | 3 |
| Karlstad, Ø | 3 |
| Klungsøyr, K | 3 |
| Odsbu, I | 3 |
| Reutfors, J | 3 |
| Selmer, RM | 3 |
| Ulrichsen, SP | 3 |
| Du, Y | 2 |
| Fang, W | 1 |
| Huang, W | 1 |
| Xu, Q | 2 |
| Gong, J | 2 |
| Xia, N | 2 |
| Zhu, Z | 2 |
| Wang, X | 2 |
| Zheng, R | 2 |
| Xu, H | 2 |
| Pekoz, MT | 1 |
| Aslan-Kara, K | 1 |
| Tekin, B | 1 |
| Gurses, C | 1 |
| Yeni, SN | 1 |
| Bozdemir, H | 1 |
| Keskin-Guler, S | 1 |
| Ataklı, D | 1 |
| Gul, G | 1 |
| Eren, F | 1 |
| Sarı, H | 1 |
| Gul, ZB | 1 |
| Ceyhan-Dirican, A | 1 |
| Genc, F | 1 |
| Bicer-Gomceli, Y | 1 |
| Ozkara, C | 1 |
| Delil, S | 1 |
| Atalar, AC | 1 |
| Bebek, N | 1 |
| Baykan, B | 1 |
| Bora, İ | 1 |
| Bican-Demir, A | 1 |
| Mısırlı, CH | 1 |
| Tutkavul, K | 1 |
| Velioglu, SK | 1 |
| Ilhan-Algin, D | 1 |
| Erdinc, O | 1 |
| Saygi, S | 1 |
| Tezer-Fılık, I | 1 |
| Apaydın-Dogan, E | 1 |
| Akyol, A | 1 |
| Kamisli, O | 2 |
| Yalcın, AD | 1 |
| Cakmak, G | 1 |
| Ersoy, A | 1 |
| Ustun-Ozek, S | 1 |
| Halac, G | 1 |
| Kutlu, G | 1 |
| Tantik-Pak, A | 1 |
| Yücel, SP | 1 |
| Bromley, RL | 7 |
| Bullen, P | 1 |
| Campbell, E | 2 |
| Craig, J | 6 |
| Ingham, A | 1 |
| Irwin, B | 2 |
| Jackson, C | 1 |
| Kelly, T | 1 |
| Morrow, J | 3 |
| Rushton, S | 1 |
| García-Fiñana, M | 3 |
| Hughes, DM | 1 |
| Winterbottom, J | 1 |
| Wood, A | 1 |
| Yates, LM | 1 |
| Clayton-Smith, J | 8 |
| Lin, J | 1 |
| Barry, JM | 1 |
| French, JA | 2 |
| Harden, CL | 3 |
| Bromley, R | 1 |
| Adab, N | 1 |
| Bluett-Duncan, M | 2 |
| Edwards, K | 1 |
| Greenhalgh, J | 1 |
| Hill, RA | 1 |
| Jackson, CF | 1 |
| Khanom, S | 1 |
| McGinty, RN | 1 |
| Tudur Smith, C | 1 |
| Pulman, J | 1 |
| Marson, AG | 1 |
| Vajda, F | 7 |
| O'Brien, T | 3 |
| Graham, J | 8 |
| Hitchcock, A | 4 |
| Perucca, P | 1 |
| Lander, C | 4 |
| Eadie, M | 5 |
| Kardoost, M | 1 |
| Hajizadeh-Saffar, E | 1 |
| Ghorbanian, MT | 1 |
| Ghezelayagh, Z | 1 |
| Pooshang Bagheri, K | 1 |
| Behdani, M | 1 |
| Habibi-Anbouhi, M | 1 |
| Keni, RR | 1 |
| Jose, M | 1 |
| A S, R | 1 |
| Baishya, J | 1 |
| Sankara Sarma, P | 1 |
| Thomas, SV | 3 |
| Söderberg Löfdal, K | 1 |
| Angus-Leppan, H | 1 |
| Moghim, MM | 1 |
| Cock, H | 1 |
| Kinton, L | 1 |
| Synnott Wells, M | 1 |
| Shankar, R | 1 |
| Huber-Mollema, Y | 2 |
| van Iterson, L | 1 |
| Oort, FJ | 2 |
| Lindhout, D | 8 |
| Rodenburg, R | 2 |
| Clark, CT | 4 |
| Jeon, JY | 1 |
| Bae, JG | 1 |
| Kim, KT | 1 |
| Cho, YW | 1 |
| Kamali, M | 1 |
| Johari, H | 1 |
| Hami, J | 1 |
| Furugen, A | 1 |
| Wiggs, KK | 1 |
| Rickert, ME | 1 |
| Sujan, AC | 1 |
| Quinn, PD | 1 |
| Larsson, H | 1 |
| Lichtenstein, P | 1 |
| Oberg, AS | 1 |
| D'Onofrio, BM | 1 |
| Daugaard, CA | 2 |
| Pedersen, L | 1 |
| Markoula, S | 1 |
| Siarava, E | 1 |
| Kostoulas, C | 1 |
| Zikopoulos, A | 1 |
| Georgiou, I | 1 |
| Kaplan, YC | 1 |
| Demir, O | 1 |
| Kakumoto, M | 1 |
| Shimokawa, K | 1 |
| Ueshima, S | 1 |
| Hira, D | 1 |
| Okano, T | 1 |
| Wang, ML | 1 |
| Tao, YY | 1 |
| Sun, XY | 1 |
| Guo, Y | 2 |
| Wang, ZY | 1 |
| Cao, YF | 1 |
| Zhao, L | 1 |
| Tetro, N | 1 |
| Hamed, R | 1 |
| Berman, E | 1 |
| Eyal, S | 1 |
| Knight, R | 1 |
| Wittkowski, A | 1 |
| Toffa, DH | 1 |
| Nguyen, DK | 1 |
| Clavenna, A | 1 |
| Campi, R | 1 |
| Putignano, D | 1 |
| Fortino, I | 1 |
| Bonati, M | 1 |
| Pariente, G | 1 |
| Leibson, T | 1 |
| Shulman, T | 1 |
| Adams-Webber, T | 1 |
| Barzilay, E | 1 |
| Nulman, I | 2 |
| Wesseloo, R | 1 |
| Liu, X | 1 |
| Kushner, SA | 1 |
| Munk-Olsen, T | 1 |
| Bergink, V | 1 |
| Patorno, E | 2 |
| Huybrechts, KF | 2 |
| Bateman, BT | 2 |
| Desai, RJ | 2 |
| Mogun, H | 2 |
| Cohen, LS | 1 |
| Hernandez-Diaz, S | 4 |
| Diav-Citrin, O | 1 |
| Shechtman, S | 1 |
| Zvi, N | 1 |
| Finkel-Pekarsky, V | 1 |
| Ornoy, A | 2 |
| Kong, L | 1 |
| Zhou, T | 1 |
| Wang, B | 1 |
| Gao, Z | 1 |
| Wang, C | 1 |
| Veroniki, AA | 1 |
| Rios, P | 1 |
| Cogo, E | 1 |
| Straus, SE | 1 |
| Finkelstein, Y | 1 |
| Kealey, R | 1 |
| Reynen, E | 1 |
| Soobiah, C | 1 |
| Thavorn, K | 1 |
| Hutton, B | 1 |
| Hemmelgarn, BR | 1 |
| Yazdi, F | 1 |
| D'Souza, J | 1 |
| MacDonald, H | 1 |
| Tricco, AC | 1 |
| Cohen-Israel, M | 1 |
| Berger, I | 1 |
| Martonovich, EY | 1 |
| Klinger, G | 1 |
| Stahl, B | 1 |
| Linder, N | 1 |
| Wiedemann, K | 1 |
| Stüber, T | 1 |
| Rehn, M | 1 |
| Frieauff, E | 1 |
| Narenji Sani, R | 1 |
| Keramati, K | 1 |
| Saberi, N | 1 |
| Moezifar, M | 1 |
| Mahdavi, A | 1 |
| Patel, N | 1 |
| Viguera, AC | 2 |
| Baldessarini, RJ | 2 |
| Graham, RK | 1 |
| Tavella, G | 1 |
| Parker, GB | 1 |
| Petrenaite, V | 3 |
| Öhman, I | 6 |
| Ekström, L | 1 |
| Sæbye, D | 1 |
| Hansen, TF | 1 |
| Sabers, A | 11 |
| Reimers, A | 3 |
| Yalın, OÖ | 1 |
| Uludüz, D | 1 |
| Özge, A | 1 |
| Battino, D | 5 |
| Bonizzoni, E | 4 |
| Perucca, E | 7 |
| Thangaratinam, S | 2 |
| Marlin, N | 1 |
| Newton, S | 1 |
| Weckesser, A | 1 |
| Bagary, M | 2 |
| Greenhill, L | 2 |
| Rikunenko, R | 1 |
| D'Amico, M | 1 |
| Rogozińska, E | 1 |
| Kelso, A | 1 |
| Hard, K | 1 |
| Coleman, J | 1 |
| Moss, N | 1 |
| Roberts, T | 1 |
| Middleton, L | 1 |
| Dodds, J | 1 |
| Pullen, A | 1 |
| Eldridge, S | 1 |
| Pirie, A | 1 |
| Denny, E | 1 |
| McCorry, D | 2 |
| Khan, KS | 2 |
| Galappatthy, P | 1 |
| Liyanage, CK | 1 |
| Lucas, MN | 1 |
| Jayasekara, DTLM | 1 |
| Abhayaratna, SA | 1 |
| Weeraratne, C | 1 |
| De Abrew, K | 1 |
| Gunaratne, PS | 1 |
| Gamage, R | 1 |
| Wijeyaratne, CN | 1 |
| Wisner, KL | 3 |
| Allien, S | 1 |
| Lau, C | 2 |
| Barnard, S | 1 |
| Callisto, SP | 1 |
| Paulzen, M | 2 |
| Stingl, JC | 1 |
| Augustin, M | 1 |
| Saßmannshausen, H | 1 |
| Franz, C | 1 |
| Gründer, G | 2 |
| Schoretsanitis, G | 1 |
| Walker, DI | 1 |
| Perry-Walker, K | 1 |
| Finnell, RH | 2 |
| Pennell, KD | 1 |
| Tran, V | 1 |
| May, RC | 1 |
| McElrath, TF | 1 |
| Jones, DP | 1 |
| Cohen, MJ | 3 |
| May, R | 1 |
| Loblein, H | 1 |
| Conrad, T | 1 |
| Baker, GA | 7 |
| Kalayjian, LA | 6 |
| Kanner, A | 4 |
| Liporace, JD | 5 |
| Privitera, M | 4 |
| Loring, DW | 6 |
| Richards, N | 1 |
| Reith, D | 1 |
| Stitely, M | 1 |
| Smith, A | 1 |
| Ding, Y | 1 |
| Tan, X | 1 |
| Zhang, S | 1 |
| Wilson, KL | 1 |
| Alexander, JM | 1 |
| Rihtman, T | 1 |
| Parush, S | 1 |
| Klein, AM | 1 |
| Perel, JM | 1 |
| Helsel, J | 1 |
| Pirie, DA | 1 |
| Al Wattar, BH | 1 |
| Pirie, AM | 1 |
| Houston, V | 1 |
| Siddiqua, A | 1 |
| Doug, M | 1 |
| Lee, SH | 1 |
| Kang, JW | 1 |
| Lin, T | 1 |
| Lee, JE | 1 |
| Jin, DI | 1 |
| Kennedy, F | 1 |
| Russell, A | 1 |
| Smithson, WH | 1 |
| Parsons, L | 1 |
| Morrison, PJ | 1 |
| Liggan, B | 1 |
| Delanty, N | 1 |
| Hunt, SJ | 2 |
| Deligiannidis, KM | 2 |
| Byatt, N | 1 |
| Freeman, MP | 1 |
| Verrotti, A | 1 |
| Scaparrotta, A | 1 |
| Cofini, M | 1 |
| Chiarelli, F | 1 |
| Tiboni, GM | 1 |
| Sinclair, S | 1 |
| Cunnington, M | 3 |
| Messenheimer, J | 1 |
| Weil, J | 1 |
| Cragan, J | 1 |
| Lowensohn, R | 1 |
| Yerby, M | 2 |
| Tennis, P | 4 |
| Vajda, FJ | 8 |
| O'Brien, TJ | 5 |
| Lander, CM | 4 |
| Eadie, MJ | 3 |
| Briggs, M | 2 |
| Cheyne, CP | 1 |
| Gummery, A | 1 |
| Kneen, R | 2 |
| Mawer, G | 2 |
| Shallcross, R | 2 |
| Klein, P | 1 |
| Watson, H | 1 |
| Cheong, J | 1 |
| Lammertz, SE | 1 |
| Veselinovic, T | 1 |
| Goecke, TW | 1 |
| Hiemke, C | 1 |
| Janszky, J | 1 |
| Dalili, H | 1 |
| Nayeri, F | 1 |
| Shariat, M | 1 |
| Asgarzadeh, L | 1 |
| Soysal, H | 1 |
| Doğan, Z | 1 |
| Khan, SJ | 1 |
| Fersh, ME | 1 |
| Ernst, C | 1 |
| Klipstein, K | 1 |
| Albertini, ES | 1 |
| Lusskin, SI | 1 |
| Vanya, M | 1 |
| Devosa, I | 1 |
| Szok, D | 1 |
| Bártfai, G | 1 |
| Dolk, H | 2 |
| Wang, H | 1 |
| Loane, M | 2 |
| Morris, J | 2 |
| Garne, E | 1 |
| Addor, MC | 1 |
| Arriola, L | 1 |
| Bakker, M | 1 |
| Barisic, I | 1 |
| Doray, B | 1 |
| Gatt, M | 1 |
| Kallen, K | 1 |
| Khoshnood, B | 1 |
| Klungsoyr, K | 1 |
| Lahesmaa-Korpinen, AM | 1 |
| Latos-Bielenska, A | 1 |
| Mejnartowicz, JP | 1 |
| Nelen, V | 1 |
| Neville, A | 1 |
| O'Mahony, M | 1 |
| Pierini, A | 1 |
| Rißmann, A | 1 |
| Tucker, D | 1 |
| Wellesley, D | 1 |
| Wiesel, A | 1 |
| de Jong-van den Berg, LT | 3 |
| Martinez Ferri, M | 1 |
| Peña Mayor, P | 1 |
| Perez López-Fraile, I | 1 |
| Escartin Siquier, A | 1 |
| Martin Moro, M | 1 |
| Forcadas Berdusan, M | 1 |
| Prakash, C | 1 |
| Hatters-Friedman, S | 1 |
| Moller-Olsen, C | 1 |
| North, A | 1 |
| Levesque, S | 1 |
| Riley, C | 1 |
| Espinera, AR | 1 |
| Gavvala, J | 1 |
| Bellinski, I | 1 |
| Kennedy, J | 1 |
| Macken, MP | 1 |
| Narechania, A | 1 |
| Templer, J | 1 |
| VanHaerents, S | 1 |
| Schuele, SU | 1 |
| Gerard, EE | 1 |
| Shih, JJ | 1 |
| Whitlock, JB | 1 |
| Chimato, N | 1 |
| Vargas, E | 1 |
| Karceski, SC | 1 |
| Frank, RD | 1 |
| Franco, V | 2 |
| Mazzucchelli, I | 1 |
| Gatti, G | 1 |
| Specchio, LM | 1 |
| La Neve, A | 1 |
| Papantonio, A | 1 |
| Ozkaynakçi, AE | 1 |
| Jentink, J | 2 |
| Sethi, NK | 1 |
| Cetinkaya, M | 1 |
| Ozkan, H | 1 |
| Köksal, N | 1 |
| Sellner, J | 1 |
| Buonomano, R | 1 |
| Nedeltchev, K | 1 |
| Findling, O | 1 |
| Schroth, G | 1 |
| Surbek, DV | 1 |
| Leib, SL | 1 |
| Fotopoulou, C | 1 |
| Kretz, R | 1 |
| Bauer, S | 1 |
| Schefold, JC | 1 |
| Schmitz, B | 2 |
| Dudenhausen, JW | 1 |
| Henrich, W | 1 |
| Ackers, R | 1 |
| Besag, FM | 1 |
| Wade, A | 1 |
| Murray, ML | 1 |
| Wong, IC | 1 |
| Craig, JJ | 1 |
| Morrow, JI | 1 |
| Vieker, S | 1 |
| Thiel, M | 1 |
| Längler, A | 1 |
| López-Fraile, IP | 1 |
| Cid, AO | 1 |
| Juste, AO | 1 |
| Modrego, PJ | 1 |
| Browning, N | 3 |
| Combs-Cantrell, DT | 3 |
| Cohen, M | 2 |
| Chen, H | 1 |
| Yang, K | 1 |
| Choi, S | 1 |
| Fischer, JH | 1 |
| Jeong, H | 1 |
| Motamedi, M | 1 |
| Karvigh, SA | 1 |
| Sahraian, MA | 1 |
| Azimi, AR | 1 |
| Navardi, S | 1 |
| Montouris, G | 1 |
| Abou-Khalil, B | 1 |
| Wakil, L | 1 |
| Epperson, CN | 1 |
| Gonzalez, J | 1 |
| O'Reardon, JP | 1 |
| Kim, DR | 1 |
| Hitchcock, AA | 2 |
| Berwaerts, K | 1 |
| Sienaert, P | 1 |
| De Fruyt, J | 1 |
| Nordmo, E | 1 |
| Aronsen, L | 1 |
| Wasland, K | 1 |
| Småbrekke, L | 1 |
| Vorren, S | 1 |
| McVearry, KM | 1 |
| Gaillard, WD | 1 |
| VanMeter, J | 1 |
| Miskov, S | 1 |
| Gjergja-Juraski, R | 1 |
| Cvitanović-Sojat, L | 1 |
| Bakulić, TI | 1 |
| Fucić, A | 1 |
| Bosnjak-Pasić, M | 1 |
| Mikula, I | 1 |
| Demarin, V | 1 |
| Forcelli, PA | 2 |
| Janssen, MJ | 1 |
| Stamps, LA | 1 |
| Sweeney, C | 1 |
| Vicini, S | 1 |
| Gale, K | 2 |
| Graham, JE | 1 |
| Galbally, M | 1 |
| Roberts, M | 1 |
| Buist, A | 1 |
| Madadi, P | 1 |
| Ito, S | 1 |
| Wegner, I | 1 |
| Edelbroek, P | 2 |
| de Haan, GJ | 2 |
| Sander, JW | 1 |
| Iniesta, I | 1 |
| Berle, JØ | 1 |
| Solberg, DK | 1 |
| Spigset, O | 1 |
| Østby, L | 1 |
| Stuen, I | 1 |
| Sundby, E | 1 |
| Helde, G | 1 |
| Bråthen, G | 1 |
| Brodtkorb, E | 1 |
| Cummings, C | 1 |
| Stewart, M | 1 |
| Stevenson, M | 1 |
| Nelson, J | 1 |
| Yger, M | 1 |
| Khalil, A | 1 |
| Hammoudi, N | 1 |
| Muresan, IP | 1 |
| Alamowitch, S | 1 |
| Kondratyev, A | 1 |
| Cunnington, MC | 2 |
| Weil, JG | 1 |
| Messenheimer, JA | 1 |
| Ferber, S | 2 |
| Holmes, LB | 3 |
| Mittendorf, R | 1 |
| Shen, A | 1 |
| Smith, CR | 2 |
| Roten, A | 1 |
| Abelaira, HM | 1 |
| Réus, GZ | 1 |
| Ribeiro, KF | 1 |
| Zappellini, G | 1 |
| Cipriano, AL | 1 |
| Scaini, G | 1 |
| Streck, EL | 1 |
| Quevedo, J | 1 |
| Boersma, C | 1 |
| Postma, MJ | 1 |
| Moore, JL | 1 |
| Aggarwal, P | 1 |
| Dodd, S | 1 |
| Horgan, D | 1 |
| Vlasov, PN | 1 |
| Dranko, DV | 1 |
| Agranovich, OV | 1 |
| Terada, K | 1 |
| Inoue, Y | 1 |
| Koo, J | 1 |
| Zavras, A | 1 |
| Mawer, GE | 1 |
| Cheyne, C | 1 |
| Lucas, SB | 1 |
| Tran, TA | 1 |
| Leppik, IE | 1 |
| Blesi, K | 1 |
| Sathanandan, ST | 1 |
| Remmel, R | 1 |
| Smyth, MD | 1 |
| Barbaro, NM | 1 |
| Baraban, SC | 1 |
| Eldridge, RR | 1 |
| Kalkman, HO | 1 |
| Ozkinay, F | 1 |
| Cogulu, O | 1 |
| Gunduz, C | 1 |
| Yilmaz, D | 1 |
| Kultursay, N | 1 |
| Choi, H | 1 |
| Morrell, MJ | 1 |
| Myllynen, PK | 1 |
| Pienimäki, PK | 1 |
| Vähäkangas, KH | 1 |
| Yerby, MS | 1 |
| Dam, M | 1 |
| A-Rogvi-Hansen, B | 1 |
| Boas, J | 1 |
| Sidenius, P | 1 |
| Laue Friis, M | 1 |
| Alving, J | 1 |
| Dahl, M | 1 |
| Ankerhus, J | 1 |
| Mouritzen Dam, A | 1 |
| Newport, DJ | 3 |
| Stowe, ZN | 3 |
| Helmers, SL | 1 |
| Montgomery, JQ | 1 |
| Henry, TR | 1 |
| Padmanabhan, R | 1 |
| Abdulrazzaq, YM | 1 |
| Bastaki, SM | 1 |
| Shafiullah, M | 1 |
| Chandranath, SI | 1 |
| Liporace, J | 1 |
| Kao, A | 1 |
| D'Abreu, A | 1 |
| Bowden, CL | 1 |
| Asnis, GM | 1 |
| Ginsberg, LD | 1 |
| Bentley, B | 1 |
| Leadbetter, R | 1 |
| White, R | 1 |
| Wu, SP | 1 |
| Shyu, MK | 1 |
| Liou, HH | 1 |
| Gau, CS | 1 |
| Lin, CJ | 1 |
| Yonkers, KA | 1 |
| Stowe, Z | 1 |
| Leibenluft, E | 1 |
| Cohen, L | 1 |
| Miller, L | 1 |
| Manber, R | 1 |
| Viguera, A | 1 |
| Suppes, T | 1 |
| Altshuler, L | 1 |
| Segers, J | 1 |
| Engelsman, M | 1 |
| Dévilé-Notschaele, M | 1 |
| Augustijn, P | 1 |
| Daoud, AS | 1 |
| Bataineh, H | 1 |
| Otoom, S | 1 |
| Abdul-Zahra, E | 1 |
| Solinas, C | 3 |
| Cook, M | 1 |
| Karlov, VA | 1 |
| Curtis, V | 1 |
| Gaily, E | 1 |
| Gentile, S | 2 |
| Voermans, NC | 1 |
| Zwarts, MJ | 1 |
| Renier, WO | 1 |
| Bloem, BR | 1 |
| Hansen-Schwartz, J | 1 |
| Eisenberg, E | 1 |
| Shifrin, A | 1 |
| Krivoy, N | 1 |
| Hauser, WA | 1 |
| Brodie, MJ | 1 |
| Candito, M | 1 |
| Guéant, JL | 1 |
| Naimi, M | 1 |
| Bongain, A | 1 |
| Van Obberghen, E | 1 |
| Smith, JC | 1 |
| Wolff, MC | 1 |
| Dubnov-Raz, G | 1 |
| Shapiro, R | 1 |
| Merlob, P | 1 |
| Luef, G | 2 |
| Pittschieler, S | 1 |
| Quartey, G | 1 |
| Vozzi, F | 1 |
| Shor, S | 1 |
| Koren, G | 1 |
| Prabhu, LV | 1 |
| Nasar, MA | 1 |
| Rai, R | 1 |
| Madhyastha, S | 1 |
| Singh, G | 1 |
| Peng, L | 1 |
| Ritchie, JC | 1 |
| Koganti, A | 1 |
| Holley, DK | 1 |
| Newman, M | 1 |
| Beck, O | 1 |
| Vitols, S | 3 |
| Manent, JB | 1 |
| Jorquera, I | 1 |
| Ben-Ari, Y | 1 |
| Represa, A | 1 |
| Calamaras, MR | 1 |
| Juric, S | 1 |
| Knight, B | 1 |
| Baldwin, EJ | 1 |
| Habecker, E | 1 |
| Glassman, L | 1 |
| Wong, SL | 1 |
| Wyszynski, DF | 1 |
| Buchanan, N | 1 |
| Richens, A | 1 |
| Appleton, RE | 1 |
| Quattrini, A | 1 |
| Ortenzi, A | 1 |
| Paggi, A | 1 |
| Foschi, N | 1 |
| Quattrini, C | 1 |
| Rambeck, B | 1 |
| Kurlemann, G | 1 |
| Stodieck, SR | 1 |
| May, TW | 1 |
| Jürgens, U | 1 |
| Mackay, FJ | 1 |
| Wilton, LV | 1 |
| Pearce, GL | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
| Tueth, MJ | 1 |
| Murphy, TK | 1 |
| Evans, DL | 1 |
| Matar, KM | 1 |
| Nicholls, PJ | 1 |
| Tekle, A | 1 |
| Bawazir, SA | 1 |
| Al-Hassan, MI | 1 |
| Reiff-Eldridge, R | 1 |
| Heffner, CR | 1 |
| Ephross, SA | 1 |
| Tennis, PS | 1 |
| White, AD | 1 |
| Andrews, EB | 1 |
| Chaudron, LH | 1 |
| Jefferson, JW | 1 |
| Marchi, NS | 1 |
| Azoubel, R | 1 |
| Tognola, WA | 1 |
| Beghi, E | 1 |
| Annegers, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physiological-based Pharmacokinetics Approach to Determine the Extent of Drug Exposure of Antiseizure Medications During Pregnancy and Breastfeeding[NCT05450978] | 60 participants (Anticipated) | Observational [Patient Registry] | 2022-07-20 | Recruiting | |||
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| Pharmacokinetics of Lamotrigine in Pregnant and Postpartum Women With Bipolar Disorder[NCT01996293] | 30 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Lamotrigine Pregnancy Registry (LAM05)[NCT01064297] | 3,416 participants (Actual) | Observational | 2001-11-30 | Completed | |||
| Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum[NCT02163434] | Phase 2 | 31 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study[NCT00021866] | 331 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| Study of Maternal Pharmacokinetic and Placental Transfer of Levetiracetam[NCT04117425] | 50 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | |||
| Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions[NCT02292056] | 50 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | |||
| The Sumatriptan and Naratriptan Pregnancy Registry[NCT01059604] | 868 participants (Actual) | Observational [Patient Registry] | 2001-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy with valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 14 |
| First Exposure During Second Trimester | 1 |
| First Exposure During Third Trimester | 0 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 1 |
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy without valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 12 |
| First Exposure During Second Trimester | 0 |
| First Exposure During Third Trimester | 1 |
| All Trimesters | 13 |
Among lamotrigine monotherapy exposures: live births, fetal deaths, induced abortions with birth defects, and live births without defects. Due to the likelihood of inconsistent identification of birth defects among spontaneous losses, fetal deaths, and induced abortions without reported birth defects, these offspring were not included in analyses. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 35 |
| First Exposure During Second Trimester | 4 |
| First Exposure During Third Trimester | 1 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 40 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine monotherapy. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of major congenital malformations are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 31 | 1 | 3 | 1523 | 10 | 33 | 98 |
| First Exposure During Second Trimester | 4 | 0 | 0 | 91 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 17 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy with valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 14 | 0 | 2 | 134 | 1 | 4 | 6 |
| First Exposure During Second Trimester | 1 | 0 | 0 | 6 | 1 | 0 | 0 |
| First Exposure During Third Trimester | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The number of live births, fetal deaths with pregnancy loss occurring >=20 weeks gestation, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy without valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. Although birth defects may not have been reported, they cannot be ruled out. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 11 | 0 | 1 | 418 | 3 | 19 | 22 |
| First Exposure During Second Trimester | 0 | 0 | 0 | 25 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy with valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydrocephalus/spina bifida | Meningomyelocele | Microcephaly | Orofacial clefts | Cardiac septal defects | Transposition of great vessels | Ventricular hypoplasia | Pulmonary stenosis | Pyloric stenosis | Gastroschisis | Club foot | Polydactyly | |
| Doses Lower Than Prescribed | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Prescribed Doses | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy without valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neural tube defect | Cardiac septal defect/murmur | Coarctation of aorta | Tetralogy of Fallot | Esophageal defects | Hypospadias | Hydroencephalopathy | Omphalocele | Extra digit | Skin tags on ear | |
| Doses Higher Than Prescribed | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Doses Lower Than Prescribed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Prescribed Doses | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
The number of infants with the reported MCM following first trimester lamotrigine monotherapy exposure were counted. Registry personnel contacted the enrolling physician to obtain information on the pregnancy outcome, lamotrigine dosing and duration of exposure, and use of concomitant antiepileptic drugs during pregnancy. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anencephaly | Orofacial clefts | Hypoplastic left heart/left ventricle hypoplasia | Transposition of great vessels | Ventricular septal defects | Minor heart defect, unspecified | Pulmonary stenosis | Hydronephrosis | Renal defect (absent, polysystic, fluid on kidney) | Cortical dysplasis | Hypospadias | Pyloric stenosis | Diaphragmatic hernia | Congenital atresia of anus | Hip dislocation | Club feet | Polydactyly | Epidermolysis bullosa | Light spot across entire abdomen | |
| Dose Higher Than Prescribed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Doses Lower Than Prescribed | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Prescribed Doses | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Unknown Maximal Dose in Exposed Trimester | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Score range: 6-30 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 6.35 |
| Metoclopramide | 13.22 |
Score range: 2-10 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 2.01 |
| Metoclopramide | 3.69 |
Score range: 0-15 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 7.86 |
| Metoclopramide | 4.01 |
Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 0.67 |
| Metoclopramide | 0.14 |
Score range: 0-4 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 2.22 |
| Metoclopramide | 0.63 |
(NCT02163434)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 5 |
| Metoclopramide | 5 |
51 reviews available for lamotrigine and Pregnancy
| Article | Year |
|---|---|
Adverse fetal and neonatal outcomes following in-utero exposure to oxcarbazepine: A systematic review and meta-analysis.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Observational Studies as Topic; Oxcarbazepin | 2022 |
Dosage Optimization of Lamotrigine in Pregnancy: A Pharmacometric Approach Using Modeling and Simulation.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; Triazine | 2022 |
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.
Topics: Child; Cohort Studies; Epilepsy; Female; Humans; Lamotrigine; Male; Phenytoin; Pregnancy; Prenatal E | 2023 |
Psychotropic drug use in perinatal women with bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Elimination Routes; Fe | 2020 |
[Transfer Mechanisms of Compounds between Mother and Fetus/Infant Aimed for Optimized Medication during Pregnancy and Breastfeeding].
Topics: Anticonvulsants; Benzodiazepines; Biological Transport; Breast Feeding; Cell Line; Epilepsy; Female; | 2020 |
Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.
Topics: Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam | 2021 |
Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review.
Topics: Anticonvulsants; Child; Female; Gabapentin; Humans; Lacosamide; Lamotrigine; Levetiracetam; Oxcarbaz | 2021 |
Neurodevelopment Following Exposure to Antiseizure Medications in Utero: A Review.
Topics: Anticonvulsants; Child; Epilepsy; Female; Humans; Lamotrigine; Oxcarbazepine; Pregnancy; Pregnancy C | 2021 |
Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 2017 |
The risks associated with the use of lamotrigine during pregnancy.
Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Developmental Disabilities; Excitatory Amino Acid Ant | 2018 |
Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis.
Topics: Anticonvulsants; Autistic Disorder; Bayes Theorem; Breast Feeding; Carbamazepine; Child; Epilepsy; F | 2017 |
Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period?
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Bre | 2018 |
Treatment of Peripartum Bipolar Disorder.
Topics: Bipolar Disorder; Electroconvulsive Therapy; Female; Humans; Lamotrigine; Peripartum Period; Phototh | 2018 |
Seizures and intracranial hemorrhage.
Topics: Anticonvulsants; Carbamazepine; Congenital Abnormalities; Eclampsia; Epilepsy; Female; Folic Acid; H | 2013 |
Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis.
Topics: Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Compli | 2014 |
Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.
Topics: Antidepressive Agents; Carbamazepine; Drug Monitoring; Female; Humans; Lamotrigine; Mood Disorders; | 2014 |
Developmental neurotoxicity and anticonvulsant drugs: a possible link.
Topics: Animals; Anticonvulsants; Breast Feeding; Carbamazepine; Cognition Disorders; Developmental Disabili | 2014 |
Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Humans; International Cooperation; Lamotrigine | 2014 |
Lamotrigine effects on breastfed infants.
Topics: Adult; Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant; Infant, Newborn; Lactation | 2015 |
Effects of phenytoin and lamotrigine treatment on serum BDNF levels in offsprings of epileptic rats.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Disease Models, Animal; Electroencephal | 2016 |
Bipolar Disorder in Pregnancy and Postpartum: Principles of Management.
Topics: Antipsychotic Agents; Bipolar Disorder; Electroconvulsive Therapy; Female; Humans; Lactation; Lamotr | 2016 |
[Preconceptional and perinatal challenges of pregnancy in women with epilepsy].
Topics: Adult; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epileps | 2016 |
Epilepsy treatment in adults and adolescents: Expert opinion, 2016.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Depression; Double-Blind Method; Dru | 2017 |
Epileptic disorders in pregnancy: an overview.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Folic Acid; Hemorrhag | 2008 |
Managing antiepileptic drugs during pregnancy and lactation.
Topics: Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Humans; Infant; Lactation; Lamotri | 2009 |
The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Topics: Anticonvulsants; Congenital Abnormalities; Delayed-Action Preparations; Drug Design; Epilepsy, Gener | 2009 |
Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Breast Feeding; Female; Follow-Up Studies; Humans; Infant | 2009 |
The teratogenic risk of antiepileptic drug polytherapy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Female; Fetal Di | 2010 |
[Teratogenic effects of lamotrigine in women with bipolar disorder].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Epilepsy; Fema | 2009 |
Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium.
Topics: Anticonvulsants; Antimanic Agents; Depressive Disorder; Drug Monitoring; Epilepsy; Female; Humans; L | 2010 |
Mood stabilizers in pregnancy: a systematic review.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepin | 2010 |
[Treatment of bipolar disorder during pregnancy and in the postpartum period].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Contraindications; Female; Humans; Lactati | 2011 |
Lamotrigine use in pregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Maternal-Fetal Exchange; Pregnancy; Triazine | 2012 |
Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Epilepsy; Female; Humans; Lamotr | 2013 |
[Lamotrigine in treatment of women with epilepsy].
Topics: Abnormalities, Drug-Induced; Age Factors; Anticonvulsants; Breast Feeding; Contraceptive Agents, Fem | 2011 |
Antischizophrenic activity independent of dopamine D2 blockade.
Topics: Amino Acid Transport System X-AG; Animals; Antipsychotic Agents; Brain Chemistry; Dopamine D2 Recept | 2002 |
Review of lamotrigine and its clinical applications in epilepsy.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Child; Dose-Response Relationship, Drug; Epil | 2003 |
Antiepileptic drug pharmacokinetics during pregnancy and lactation.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetal Diseases; Fetal Hypoxia | 2003 |
[Lamotrigine in women with epilepsy. Review of present data].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Contraceptives, Oral; Dose-Response Relationship, Drug | 2003 |
Safety and tolerability of lamotrigine for bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Interactio | 2004 |
Management of bipolar disorder during pregnancy and the postpartum period.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbam | 2004 |
[Therapy of epilepsy: current strategy and tactics].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; | 2004 |
Women are not the same as men: specific clinical issues for female patients with bipolar disorder.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Counseling; Dibenzothiaze | 2005 |
Lamotrigine for neuropathic pain.
Topics: Analgesics; Drug Interactions; Drug Therapy, Combination; Expert Testimony; Female; Humans; Lamotrig | 2005 |
The case for lamotrigine monitoring in pregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Monitoring, Physiologic; Pregnancy; Triazine | 2006 |
2005 AES annual course: evidence used to treat women with epilepsy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Breast Feeding; Drug Monitoring; Drug Therapy, Combina | 2006 |
Lamotrigine in pregnancy: safety profile and the risk of malformations.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Epilepsy; Female; Folic Acid Deficiency; Huma | 2007 |
Safety of lamotrigine.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Eruptions; Epilepsy; Female; Humans; L | 1994 |
The new antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Pre | 1996 |
Special considerations: use of lithium in children, adolescents, and elderly populations.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Age Factors; Aged; Amines; Anticonvulsants | 1998 |
Mood stabilizers during breastfeeding: a review.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Breast Feeding; Carbamazepine; Cyclohexanecarbo | 2000 |
7 trials available for lamotrigine and Pregnancy
| Article | Year |
|---|---|
AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies.
Topics: Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Monitoring; Epilepsy; Female; Humans; Lamo | 2018 |
Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Fetal Blood; Humans; Inf | 2009 |
Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.
Topics: Adult; Anticonvulsants; Child; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Hum | 2013 |
Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo.
Topics: Anticonvulsants; Antipyrine; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; | 2003 |
In utero antiepileptic drug exposure: fetal death and malformations.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Cognition; Female; Fetal Death; | 2006 |
Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives.
Topics: Anticonvulsants; Contraceptives, Oral; Drug Combinations; Epilepsy; Female; Humans; Kinetics; Lamotr | 2006 |
Lamotrigine in bipolar disorder: efficacy during pregnancy.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Fe | 2008 |
162 other studies available for lamotrigine and Pregnancy
| Article | Year |
|---|---|
Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?
Topics: Anticonvulsants; Carbamazepine; Female; Humans; Lamotrigine; Levetiracetam; Pregnancy; Retrospective | 2022 |
[Women with epilepsy before and during pregnancy: a case series of outpatient counseling in a tertiary epilepsy center].
Topics: Anticonvulsants; Counseling; Epilepsy; Female; Folic Acid; Humans; Lamotrigine; Levetiracetam; Outpa | 2022 |
Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lacosamide; Lamotrigine; Levetirace | 2022 |
Evaluation of family planning methods in married women with epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Family Planning Services; Female; Humans; Lamotrigine; Levetiracet | 2022 |
Trends in the prescription of anti-seizure medicines for pregnant women outpatients with epilepsy during 2016-2020 in Japan.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Japan; Lamotrigine; Levetiracetam; Outpatients; Pregnancy | 2022 |
Monitoring of lamotrigine concentrations in mothers, colostrum, and breastfed newborns during the early postpartum period.
Topics: Anticonvulsants; Breast Feeding; Cohort Studies; Colostrum; Female; Humans; Infant, Newborn; Lamotri | 2022 |
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.
Topics: Anticonvulsants; Autism Spectrum Disorder; Autistic Disorder; Carbamazepine; Child; Cohort Studies; | 2022 |
Use of antiepileptic drugs by trimester.
Topics: Anticonvulsants; Clonazepam; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pregnancy; Retros | 2022 |
Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Male; Phenobarbital; Pregnanc | 2022 |
Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pregnancy; Seizures; V | 2023 |
Prenatal Carbamazepine Exposure and Academic Performance in Adolescents: A Population-Based Cohort Study.
Topics: Academic Performance; Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Cohort Stu | 2023 |
Assessing medical product safety during pregnancy using parameterizable tools in the sentinel distributed database.
Topics: Anticonvulsants; Female; Humans; Infant; Lamotrigine; Mothers; Pregnancy; Pregnancy Trimester, First | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Ch | 2023 |
Changes in seizure frequency and anti-seizure medication therapy during pregnancy and one year postpregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; Seizures | 2023 |
Birth outcomes in pregnant women with epilepsy: A Nationwide multicenter study from Türkiye.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant; Infant, Newborn; Lamotrigine; Preg | 2023 |
Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study.
Topics: Anticonvulsants; Child Development; Epilepsy; Female; Humans; Infant; Lamotrigine; Levetiracetam; Mo | 2023 |
External validation of the AntiEpileptic Drug Monitoring in PREgnancy (EMPiRE) model for predicting seizures in pregnant women with epilepsy.
Topics: Anticonvulsants; Carbamazepine; Cohort Studies; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam | 2023 |
Empiric dosing strategies to predict lamotrigine concentrations during pregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; Seizures | 2023 |
Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control.
Topics: Anticonvulsants; Australia; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complication | 2023 |
Genotoxicity assessment of antiepileptic drugs (AEDs) in human embryonic stem cells.
Topics: Anticonvulsants; Carbamazepine; DNA Damage; Epilepsy; Female; Human Embryonic Stem Cells; Humans; La | 2019 |
Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy.
Topics: Adult; Anticonvulsants; Carbamazepine; Female; Folic Acid; Humans; India; Lamotrigine; Levetiracetam | 2020 |
[New recommendations for antiepileptic drug therapy: the last piece in the review of epilepsy care].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pregnancy; Pre | 2020 |
Valproate risk form-Surveying 215 clinicians involving 4775 encounters.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Physicians | 2020 |
Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure.
Topics: Anticonvulsants; Carbamazepine; Child; Child Development; Cognitive Dysfunction; Female; Humans; Lam | 2020 |
Pregnancy and Epilepsy: a Korean Tertiary Epilepsy Center Review.
Topics: Adult; Anticonvulsants; Cesarean Section; Electroencephalography; Epilepsy; Female; Gestational Age; | 2020 |
Protective Effect of Flax Seed on Brain Teratogenicity Induced by Lamotrigine in Rat Fetuses.
Topics: Animals; Anticonvulsants; Body Weight; Brain; Brain Cortical Thickness; Female; Fetus; Flax; Hippoca | 2020 |
Antiseizure medication use during pregnancy and risk of ASD and ADHD in children.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2020 |
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Denmark; Developmen | 2020 |
An open study of valproate in subfertile men with epilepsy.
Topics: Adult; Anticonvulsants; Drug Substitution; Epilepsy; Female; Greece; Humans; Infertility, Male; Lamo | 2020 |
Effects of antiepileptic drugs' administration during pregnancy on the nerve cell proliferation and axonal outgrowth of human neuroblastoma SH-SY5Y nerve cells.
Topics: Anticonvulsants; Carbamazepine; Cell Line, Tumor; Cell Proliferation; Child; Epilepsy; Female; Human | 2021 |
Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.
Topics: Adult; Anticonvulsants; Drug Dosage Calculations; Drug Elimination Routes; Epilepsy; Estrogens; Fema | 2021 |
Effects of antiseizure medications on placental cells: Focus on heterodimeric placental carriers.
Topics: Anticonvulsants; Female; Humans; Lamotrigine; Levetiracetam; Placenta; Pregnancy; Valproic Acid | 2021 |
Epilepsy and Pregnancy: An Audit of Specialized Care.
Topics: Anticonvulsants; Canada; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; | 2022 |
Changes in antiepileptic drug prescriptions over a decade in childbearing women in Lombardy region, Italy.
Topics: Anticonvulsants; Drug Prescriptions; Female; Humans; Infant; Lamotrigine; Levetiracetam; Male; Pregn | 2022 |
Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: A population-based cohort study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cohort Studies; Depression, Postpartum; Female; Humans; L | 2017 |
Lithium Use in Pregnancy and the Risk of Cardiac Malformations.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cohort Studies; F | 2017 |
Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Female; Humans; Lamotrigine; | 2017 |
Short- and long-term complications of in utero exposure to lamotrigine.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; Hum | 2018 |
Fetal Valproate Syndrome - Still a Problem Today!
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cesarean Section; Drug Therapy, Combination; Ep | 2017 |
Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Brain; Drug Resistance; Drug Resistant Epilepsy; Female; | 2018 |
Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Dietary Supplements; Female; Fol | 2018 |
Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cleft Palate; Cohort Studies; Dose-Response Rel | 2018 |
UGT polymorphisms and lamotrigine clearance during pregnancy.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Glucuronosyltransferase; | 2018 |
Management of pregnant women with epilepsy who use lamotrigine.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy | 2018 |
Peripheral nerve blocks for the treatment of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) during pregnancy.
Topics: Adult; Anticonvulsants; Diagnosis, Differential; Female; Headache; Humans; Lamotrigine; Nerve Block; | 2018 |
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2018 |
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine; | 2018 |
Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age.
Topics: Adult; Anticonvulsants; Epilepsy; Estradiol; Female; Gestational Age; Humans; Lamotrigine; Metabolic | 2018 |
Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine.
Topics: Adult; Amniotic Fluid; Anticonvulsants; Female; Fetal Blood; Humans; Infant, Newborn; Lamotrigine; M | 2019 |
Metabolome-wide association study of anti-epileptic drug treatment during pregnancy.
Topics: Adult; Anticonvulsants; Carbon; Epilepsy; Female; Fetus; Folic Acid; Humans; Lamotrigine; Levetirace | 2019 |
Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsy; Female; Humans; Lamotrigine; Learning; Memor | 2019 |
A Short Communication: Lamotrigine Levels in Milk, Mothers, and Breastfed Infants During the First Postnatal Month.
Topics: Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant, Newborn; Lamotrigine; Milk, Human | 2019 |
Developmental outcomes at age four following maternal antiepileptic drug use.
Topics: Adult; Anticonvulsants; Carbamazepine; Child Development; Child, Preschool; Cohort Studies; Epilepsy | 2019 |
Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy.
Topics: Adult; Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy | 2019 |
Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Behavior Disorders; Epilepsy; Female; Humans; La | 2019 |
Use of antiepileptic drugs in women of fertile age.
Topics: Adolescent; Adult; Anticonvulsants; Denmark; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Leve | 2019 |
Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function.
Topics: Anticonvulsants; Attention; Behavior; Child; Child, Preschool; Cognition; Faculty; Female; Humans; L | 2013 |
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry.
Topics: Anticonvulsants; Carbamazepine; Female; Humans; Lamotrigine; Phenobarbital; Pregnancy; Pregnancy Com | 2013 |
Lamotrigine dosing for pregnant patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Female; Humans; Infant, Newborn; Lamotrigi | 2013 |
Lamotrigine dosing for pregnant patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Female; Humans; Infant, Newborn; Lamotrigi | 2013 |
Lamotrigine dosing for pregnant patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Female; Humans; Infant, Newborn; Lamotrigi | 2013 |
Lamotrigine dosing for pregnant patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Female; Humans; Infant, Newborn; Lamotrigi | 2013 |
Teratogenic potential of antiepileptic drugs in the zebrafish model.
Topics: Acetamides; Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Ethosuximide; Female; F | 2013 |
Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2014 |
The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy.
Topics: Anticonvulsants; Female; Fructose; Humans; Lamotrigine; Levetiracetam; Piracetam; Pregnancy; Registr | 2014 |
The teratogenicity of the newer antiepileptic drugs - an update.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetus; Fructose; Humans; Lamo | 2014 |
IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Development; Epilepsy; Female; Humans; Intellige | 2015 |
Fine-tuning risk assessment with antiepileptic drug use in pregnancy.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Lamotrigi | 2015 |
Valproate and pregnancy: think again.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Lamotrigi | 2015 |
Poor neonatal adaptation following in-utero exposure to quetiapine and lamotrigine.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Hypothyroidism; Infant, Newborn; Infa | 2015 |
Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; D | 2015 |
Lamotrigine in pregnancy - therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood.
Topics: Adult; Amniotic Fluid; Anticonvulsants; Drug Monitoring; Female; Fetal Blood; Humans; Infant, Newbor | 2015 |
[Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Contraception; Dose-Response Relationship, Drug; Drug | 2015 |
Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Case-Control Studies; Cleft Lip; Cleft Palate; | 2016 |
Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Longitu | 2018 |
Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand.
Topics: Bipolar Disorder; Calcium Channel Blockers; Female; Humans; Infant; Lamotrigine; Mental Health; New | 2016 |
Fetal exposure to lamotrigine and quetiapine in two consecutive pregnancies.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Infant, Newborn; La | 2017 |
Counseling by epileptologists affects contraceptive choices of women with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Choice Behavior; Cohort Studies; Contraception; Contraceptive Ag | 2016 |
Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium.
Topics: Adult; Anticonvulsants; Calibration; Chromatography, High Pressure Liquid; Drug Interactions; Female | 2008 |
Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?
Topics: Adolescent; Antimanic Agents; Case-Control Studies; Child; Child, Preschool; Cleft Lip; Community He | 2008 |
What is the risk of orofacial clefts from lamotrigine exposure during pregnancy?
Topics: Anticonvulsants; Cleft Lip; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Risk; Triazines | 2008 |
Unilateral radius aplasia due to lamotrigine and oxcarbazepine use in pregnancy.
Topics: Anticonvulsants; Carbamazepine; Female; Humans; Infant, Newborn; Lamotrigine; Maxillofacial Abnormal | 2008 |
A case of maternal herpes simplex virus encephalitis during late pregnancy.
Topics: Acyclovir; Adult; Anticonvulsants; Antiviral Agents; Brain; Encephalitis, Herpes Simplex; Female; He | 2009 |
Changing trends in antiepileptic drug prescribing in girls of child-bearing potential.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Child; Contraceptive Agents | 2009 |
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.
Topics: Adult; Anticonvulsants; Bias; Cleft Palate; Cohort Studies; Female; Humans; Incidence; Infant, Newbo | 2009 |
[Neonatal seizures caused by lamotrigin withdrawal?].
Topics: Adult; Anticonvulsants; Female; Humans; Infant, Newborn; Lamotrigine; Male; Maternal-Fetal Exchange; | 2009 |
Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Lamotrigine; Levetiracetam; Mat | 2009 |
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Developmental Disabilities; Dose | 2009 |
Utilization of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry.
Topics: Adult; Anticonvulsants; Child; Cross-Cultural Comparison; Drug Prescriptions; Drug Therapy, Combinat | 2009 |
Seizure frequency in pregnant women treated with lamotrigine monotherapy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Dru | 2009 |
Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy.
Topics: Adult; Animals; Anticonvulsants; Electrophoretic Mobility Shift Assay; Estradiol; Female; Glucuronid | 2009 |
Lamotrigine and twin pregnancy, incidental event or possible correlation?
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Retrospective Studies; Tri | 2009 |
Severe apnea in an infant exposed to lamotrigine in breast milk.
Topics: Adult; Apnea; Breast Feeding; Epilepsy; Female; Humans; Infant, Newborn; Lamotrigine; Male; Milk, Hu | 2009 |
A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy.
Topics: Analysis of Variance; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Creativity; Epile | 2009 |
Valproic acid: long-term effects on children exposed in utero.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Cohort Studies; Contraindications; Dose | 2009 |
Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy--aspects of pre-pregnancy counseling and drug monitoring.
Topics: Adult; Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Lamotrigine; Preconception Care; | 2009 |
Therapeutic strategies to avoid long-term adverse outcomes of neonatal antiepileptic drug exposure.
Topics: Animals; Animals, Newborn; Anticonvulsants; Corpus Striatum; Female; Humans; Lamotrigine; Mental Pro | 2010 |
Serum levels of lamotrigine during delivery in mothers and their infants.
Topics: Adolescent; Adult; Cohort Studies; Delivery, Obstetric; Epilepsy; Female; Fetal Blood; Humans; Infan | 2010 |
Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Congenital Abnormalities; Dose-Response Rel | 2010 |
Perinatal exposure to maternal lamotrigine: clinical considerations for the mother and child.
Topics: Adult; Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant, Newborn; Lactation; Lamotr | 2010 |
Effects of breastfeeding in children of women taking antiepileptic drugs.
Topics: Adult; Anticonvulsants; Breast Feeding; Carbamazepine; Child, Preschool; Cognition; Epilepsy; Female | 2010 |
Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy.
Topics: Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Monitoring; Drug Thera | 2010 |
Carbamazepine in pregnancy: Levetiracetam and lamotrigine are better options.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Contraindications; Epilepsy; Female; Hu | 2011 |
Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term.
Topics: Anticonvulsants; Blotting, Western; Case-Control Studies; Epilepsy; Female; Gene Expression Regulati | 2011 |
Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Estradiol; Female; Humans; Lamotrigine; Outpatients; P | 2011 |
Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Case-Control Studies; Child, Preschool; Developmental Disabilities; | 2011 |
Cerebral abscess due to an abnormal drainage of the superior vena cava.
Topics: Adult; Angiography; Anti-Bacterial Agents; Anticonvulsants; Brain Abscess; Echocardiography; Epileps | 2011 |
Early postnatal exposure of rats to lamotrigine, but not phenytoin, reduces seizure threshold in adulthood.
Topics: Aging; Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Female; Lamotrigine; Male; Phenyt | 2011 |
Final results from 18 years of the International Lamotrigine Pregnancy Registry.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Humans; Infant; Lamotrigine; Pregnanc | 2011 |
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epile | 2011 |
Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Canada; Carbamazepine; Cohort Studies; Drug Therapy, C | 2011 |
Teratogenicity of the newer antiepileptic drugs--the Australian experience.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Administration Schedule; Female; Fruct | 2012 |
Algorithm for lamotrigine dose adjustment before, during, and after pregnancy.
Topics: Adult; Algorithms; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2012 |
Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats.
Topics: Amygdala; Animals; Antidepressive Agents; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor | 2012 |
Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Cost-Benefit Analysis; Epil | 2012 |
Newer anticonvulsants: lamotrigine, topiramate and gabapentin.
Topics: Abnormalities, Drug-Induced; Adult; Amines; Anticonvulsants; Case-Control Studies; Child; Child, Pre | 2012 |
[Clinical application of newer anti-epileptic drugs].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; gamma- | 2012 |
Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation.
Topics: Abnormalities, Drug-Induced; Adverse Drug Reaction Reporting Systems; Amines; Anticonvulsants; Cyclo | 2013 |
The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Child; Child Development Disorders, Per | 2013 |
Lamotrigine clearance during pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; P | 2002 |
Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Anticonvulsants; Carbamazepine; Disea | 2002 |
Preliminary results on pregnancy outcomes in women using lamotrigine.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Drug Therapy, Combination; E | 2002 |
Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Chromosome Aberrations | 2003 |
Case reports of women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Lamo | 2003 |
The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.
Topics: Abortion, Induced; Anticonvulsants; Australia; Carbamazepine; Cohort Studies; Congenital Abnormaliti | 2003 |
Epilepsy and pregnancy: lamotrigine as main drug used.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adolescent; Adult; Anticonvulsants; Epilepsy; | 2004 |
The impact of pregnancy and childbirth on the metabolism of lamotrigine.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Metabolic Clearance Rate; Pregnancy; | 2004 |
Experimental studies on reproductive toxicologic effects of lamotrigine in mice.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Embryonic a | 2003 |
Concerns regarding lamotrigine and breast-feeding.
Topics: Anticonvulsants; Breast Feeding; Epilepsy; Female; Follow-Up Studies; Humans; Infant, Newborn; Lamot | 2004 |
Interaction between anticonvulsants and human placental carnitine transporter.
Topics: Acetates; Amines; Aminoisobutyric Acids; Anticonvulsants; Carnitine; Carrier Proteins; Culture Techn | 2004 |
Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study.
Topics: Adult; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Drug; Epilepsy; Female; Fetal Bl | 2004 |
The effect of Vigabatrin, Lamotrigine and Gabapentin on the fertility, weights, sex hormones and biochemical profiles of male rats.
Topics: Amines; Analgesics; Animals; Antimanic Agents; Body Weight; Cyclohexanecarboxylic Acids; Female; Fer | 2004 |
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Child; Cohort Studies; Confoundi | 2004 |
Australian pregnancy registry of women taking antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Epilepsy; Female | 2004 |
The International Lamotrigine pregnancy registry update for the epilepsy foundation.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Foundations; Global Health; Humans; | 2004 |
What can we say to women of reproductive age with epilepsy?
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; E | 2005 |
Lamotrigine and the risk of malformations in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Europe; Female; Humans; Incidence; Infant, Newborn; La | 2005 |
Lamotrigine in pregnancy and lactation.
Topics: Adult; Anticonvulsants; Epilepsies, Myoclonic; Female; Folic Acid; Humans; Infant, Newborn; Lactatio | 2005 |
Potential risks associated with high-dose valproate in pregnancy in psychiatric patients.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, D | 2005 |
[Epileptic seizures during childbirth in a patient with idiopathic generalised epilepsy].
Topics: Adult; Anticonvulsants; Cesarean Section; Clonazepam; Diazepam; Epilepsy; Epilepsy, Generalized; Epi | 2005 |
Individual changes in lamotrigine plasma concentrations during pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Postpartum Period; Pregnancy; Retrosp | 2005 |
Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsy; Femal | 2006 |
Lamotrigine and the risk of malformations in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Causality; Cross-Sectional Studies; Data Interpretatio | 2006 |
Major congenital malformations and antiepileptic drugs: prospective observations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2006 |
Antiepileptic drugs: a case report in a pregnancy with a neural tube defect.
Topics: Adult; Anticonvulsants; Female; Folic Acid; Homocysteine; Humans; Lamotrigine; Myoclonic Epilepsy, J | 2006 |
Maternal lamotrigine treatment and elevated neonatal gamma-glutamyl transpeptidase.
Topics: Anticonvulsants; Epilepsy; Female; gamma-Glutamyltransferase; Humans; Infant, Newborn; Jaundice, Neo | 2006 |
Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Databases as Topic; Dose-Res | 2007 |
Consecutive exposure to lamotrigine and citalopram during pregnancy.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depression; Drug Administration Sched | 2007 |
Teratogenicity of lamotrigine.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cleft Palate; Drug Evaluation; Epilepsy; Female; Human | 2007 |
Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency.
Topics: Adolescent; Adult; Anticonvulsants; Cohort Studies; Drug Monitoring; Epilepsy; Female; Humans; Lamot | 2008 |
Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epi | 2008 |
Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats.
Topics: Animals; Anticonvulsants; Brain; Cell Count; Cell Movement; Dose-Response Relationship, Drug; Female | 2008 |
Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites.
Topics: Adolescent; Adult; Anticonvulsants; Contraception; Epilepsy; Female; Glucuronides; Humans; Lamotrigi | 2008 |
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cleft Palate; Epilepsy; Female; Humans; Infant; Infant | 2008 |
Juvenile myoclonic epilepsy.
Topics: Adolescent; Age of Onset; Animals; Anticonvulsants; Child; Circadian Rhythm; Clonazepam; Cricetinae; | 1995 |
Lamotrigine and pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Femal | 1996 |
Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child.
Topics: Adult; Anticonvulsants; Female; Fetal Blood; Humans; Infant, Newborn; Lamotrigine; Male; Maternal-Fe | 1997 |
Safety of long-term lamotrigine in epilepsy.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Anticonvulsants; Chil | 1997 |
Lamotrigine in pregnancy and lactation: a case report.
Topics: Adult; Anticonvulsants; Breast Feeding; Chromatography, High Pressure Liquid; Dose-Response Relation | 1997 |
Effects of pregnancy on the pharmacokinetics of lamotrigine in dogs.
Topics: Anestrus; Animals; Anticonvulsants; Area Under Curve; Biological Availability; Chromatography, High | 1999 |
Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
Topics: Abnormalities, Drug-Induced; Acyclovir; Anticonvulsants; Antiviral Agents; Drug Industry; Epilepsy; | 2000 |
Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation.
Topics: Adult; Anticonvulsants; Breast Feeding; Chromatography, High Pressure Liquid; Epilepsy; Female; Feta | 2000 |
Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Brain; Female; Fetus; Lamotrigine; Pregnancy; | 2001 |
Pregnancy registries in epilepsy.
Topics: Abnormalities, Drug-Induced; Acetates; Amines; Anticonvulsants; Australia; Cross-Cultural Comparison | 2001 |